Exhibit
10.1


 


Execution
Version


 


PURCHASE
AGREEMENT


 


PURCHASE
AGREEMENT (the “Agreement”), dated as of August 4, 2020, by and between TODOS MEDICAL LTD., a State
of Israel corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability
company (the “Investor”).


 


WHEREAS:



 


Subject
to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Investor, and the Investor wishes to
buy from the Company, up to Ten Million Two Hundred Seventy-Five Thousand Dollars ($10,275,000) of the Company’s ordinary shares,
par value NIS $0.01 per share (the “Ordinary Shares”). The Ordinary Shares to be purchased hereunder (including,
without limitation, the Initial Purchase Shares (as defined herein)) are referred to herein as the “Purchase Shares.”


 


NOW
THEREFORE, in consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration,
the receipt and adequacy of which are hereby acknowledged, the Company and the Investor hereby agree as follows:


 


1.       CERTAIN
DEFINITIONS. 


 


For
purposes of this Agreement, the following terms shall have the following meanings:


 


(a)       “Accelerated
Purchase Date” means, with respect to any Accelerated Purchase made pursuant to Section 2(c) hereof, the Business
Day immediately following the applicable Purchase Date with respect to the corresponding Regular Purchase referred to in clause
(i) of the second sentence of Section 2(c) hereof.


 


(b)       “Accelerated
Purchase Floor Price” means $0.04, which shall be appropriately adjusted for any reorganization, recapitalization, non-cash
dividend, stock split or other similar transaction and, effective upon the consummation of any such reorganization, recapitalization,
non-cash dividend, stock split or other similar transaction, the Accelerated Purchase Floor Price shall mean the lower
of (i) the adjusted price and (ii) $0.30.


 


(c)       “Accelerated
Purchase Minimum Price Threshold” means, with respect to any Accelerated Purchase made pursuant to Section 2(c)
hereof, the greater of (i) seventy-five percent (75%) of the Closing Sale Price of an Ordinary Share on the applicable Purchase
Date with respect to the corresponding Regular Purchase referred to in clause (i) of the second sentence of Section 2(c)
hereof and (ii) the minimum per share price threshold set forth by the Company in the applicable Accelerated Purchase Notice.


 


(d)       “Accelerated
Purchase Notice” means, with respect to an Accelerated Purchase made pursuant to Section 2(c) hereof, an irrevocable
written notice from the Company to the Investor directing the Investor to purchase the number of Purchase Shares specified by
the Company therein as the Accelerated Purchase Share Amount to be purchased by the Investor (such specified Accelerated Purchase
Share Amount subject to adjustment in accordance with Section 2(c) hereof as necessary to give effect to the Purchase Share
amount limitations applicable to such Accelerated Purchase Share Amount as set forth in this Agreement) at the applicable Accelerated
Purchase Price on the applicable Accelerated Purchase Date for such Accelerated Purchase.


 


(e)       “Accelerated
Purchase Price” means, with respect to an Accelerated Purchase made pursuant to Section 2(c) hereof, ninety-five
percent (95%) of the lower of (i) the VWAP for the period beginning at 9:30:01 a.m., Eastern time, on the applicable Accelerated
Purchase Date, or such other time publicly announced by the Principal Market as the official open (or commencement) of trading
on the Principal Market on such applicable Accelerated Purchase Date (the “Accelerated Purchase Commencement Time”),
and ending at the earliest of (A) 4:00:00 p.m., Eastern time, on such applicable Accelerated Purchase Date, or such other time
publicly announced by the Principal Market as the official close of trading on the Principal Market on such applicable Accelerated
Purchase Date, (B) such time, from and after the Accelerated Purchase Commencement Time for such Accelerated Purchase, that the
total number (or volume) of Ordinary Shares traded on the Principal Market has exceeded the applicable Accelerated Purchase Share
Volume Maximum, and (C) such time, from and after the Accelerated Purchase Commencement Time for such Accelerated Purchase, that
the Sale Price has fallen below the applicable Accelerated Purchase Minimum Price Threshold (such earliest of (i)(A), (i)(B) and
(i)(C) above, the “Accelerated Purchase Termination Time”), and (ii) the Closing Sale Price of an Ordinary
Share on such applicable Accelerated Purchase Date (to be appropriately adjusted for any applicable reorganization, recapitalization,
non-cash dividend, stock split, reverse stock split or other similar transaction).


 






    	 



     


    

 


(f)       “Accelerated
Purchase Share Amount” means, with respect to an Accelerated Purchase made pursuant to Section 2(c) hereof, the
number of Purchase Shares directed by the Company to be purchased by the Investor in an applicable Accelerated Purchase Notice,
which number of Purchase Shares shall not exceed the lesser of (i) 300% of the number of Purchase Shares directed by the Company
to be purchased by the Investor pursuant to the corresponding Regular Purchase Notice for the corresponding Regular Purchase referred
to in clause (i) of the second sentence of Section 2(c) hereof (such corresponding Regular Purchase being subject to the
Purchase Share limitations contained in Section 2(b) hereof) and (ii) an amount equal to (A) the Accelerated Purchase Share
Percentage multiplied by (B) the total number (or volume) of Ordinary Shares traded on the Principal Market during the period
on the applicable Accelerated Purchase Date beginning at the Accelerated Purchase Commencement Time for such Accelerated Purchase
and ending at the Accelerated Purchase Termination Time for such Accelerated Purchase.


 


(g)       “Accelerated
Purchase Share Percentage” means, with respect to an Accelerated Purchase made pursuant to Section 2(c) hereof,
twenty percent (20%).


 


(h)       “Accelerated
Purchase Share Volume Maximum” means, with respect to an Accelerated Purchase made pursuant to Section 2(c) hereof,
a number of Ordinary Shares equal to (i) the number of Purchase Shares specified by the Company in the applicable Accelerated
Purchase Notice as the Accelerated Purchase Share Amount to be purchased by the Investor in such Accelerated Purchase, divided
by (ii) the Accelerated Purchase Share Percentage (to be appropriately adjusted for any applicable reorganization, recapitalization,
non-cash dividend, stock split, reverse stock split or other similar transaction).


 


(i)        “Additional
Accelerated Purchase Date” means, with respect to an Additional Accelerated Purchase made pursuant to Section 2(d)
hereof, the Business Day (i) that is the Accelerated Purchase Date with respect to the corresponding Accelerated Purchase
referred to in clause (i) of the proviso in the second sentence of Section 2(d) hereof and (ii) on which the Investor receives,
prior to 1:00 p.m., Eastern time, on such Business Day, a valid Additional Accelerated Purchase Notice for such Additional Accelerated
Purchase in accordance with this Agreement.


 


(j)        “Additional
Accelerated Purchase Floor Price” means $0.04, which shall be appropriately adjusted for any reorganization, recapitalization,
non-cash dividend, stock split or other similar transaction and, effective upon the consummation of any such reorganization, recapitalization,
non-cash dividend, stock split or other similar transaction, the Additional Accelerated Purchase Floor Price shall mean the lower
of (i) the adjusted price and (ii) $0.30.


 




    	-2-



    	 



    

 


(k)       “Additional
Accelerated Purchase Minimum Price Threshold” means, with respect to an Additional Accelerated Purchase made pursuant
to Section 2(d) hereof, the greater of (i) seventy-five percent (75%) of the Closing Sale Price of an Ordinary Share on
the Business Day immediately preceding the applicable Additional Accelerated Purchase Date with respect to such Additional Accelerated
Purchase and (ii) the minimum per share price threshold set forth by the Company in the applicable Additional Accelerated Purchase
Notice.


 


(l)        “Additional
Accelerated Purchase Notice” means, with respect to an Additional Accelerated Purchase made pursuant to Section 2(d)
hereof, an irrevocable written notice from the Company to the Investor directing the Investor to purchase the number of Purchase
Shares specified by the Company therein as the Additional Accelerated Purchase Share Amount to be purchased by the Investor (such
specified Additional Accelerated Purchase Share Amount subject to adjustment in accordance with Section 2(d) hereof as
necessary to give effect to the Purchase Share amount limitations applicable to such Additional Accelerated Purchase Share Amount
as set forth in this Agreement) at the applicable Additional Accelerated Purchase Price on the applicable Additional Accelerated
Purchase Date for such Additional Accelerated Purchase.


 


(m)      “Additional
Accelerated Purchase Price” means, with respect to an Additional Accelerated Purchase made pursuant to Section 2(d)
hereof, ninety-five percent (95%) of the lower of (i) the VWAP for the period on the applicable Additional Accelerated Purchase
Date, beginning at the latest of (A) the applicable Accelerated Purchase Termination Time with respect to the corresponding Accelerated
Purchase referred to in clause (i) of the proviso in the second sentence of Section 2(d) hereof on such Additional Accelerated
Purchase Date, (B) the applicable Additional Accelerated Purchase Termination Time with respect to the most recently completed
prior Additional Accelerated Purchase on such Additional Accelerated Purchase Date, as applicable, and (C) the time at which all
Purchase Shares subject to all prior Accelerated Purchases and Additional Accelerated Purchases (as applicable), including, without
limitation, those that have been effected on the same Business Day as the applicable Additional Accelerated Purchase Date with
respect to which the applicable Additional Accelerated Purchase relates, have theretofore been received by the Investor as DWAC
Shares in accordance with this Agreement (such latest of (i)(A), (i)(B) and (i)(C) above, the “Additional Accelerated
Purchase Commencement Time”), and ending at the earliest of (X) 4:00 p.m., Eastern time, on such Additional Accelerated
Purchase Date, or such other time publicly announced by the Principal Market as the official close of trading on the Principal
Market on such Additional Accelerated Purchase Date, (Y) such time, from and after the Additional Accelerated Purchase Commencement
Time for such Additional Accelerated Purchase, that total number (or volume) of Ordinary Shares traded on the Principal Market
has exceeded the applicable Additional Accelerated Purchase Share Volume Maximum, and (Z) such time, from and after the Additional
Accelerated Purchase Commencement Time for such Additional Accelerated Purchase, that the Sale Price has fallen below the applicable
Additional Accelerated Purchase Minimum Price Threshold (such earliest of (i)(X), (i)(Y) and (i)(Z) above, the “Additional
Accelerated Purchase Termination Time”), and (ii) the Closing Sale Price of an Ordinary Share on such Additional Accelerated
Purchase Date (to be appropriately adjusted for any applicable reorganization, recapitalization, non-cash dividend, stock split,
reverse stock split or other similar transaction).


 


(n)       “Additional
Accelerated Purchase Share Amount” means, with respect to an Additional Accelerated Purchase made pursuant to Section
2(d) hereof, the number of Purchase Shares directed by the Company to be purchased by the Investor on an Additional Accelerated
Purchase Notice, which number of Purchase Shares shall not exceed the lesser of (i) 300% of the number of Purchase Shares directed
by the Company to be purchased by the Investor pursuant to the corresponding Regular Purchase Notice for the corresponding Regular
Purchase referred to in clause (i) of the proviso in the second sentence of Section 2(d) hereof (such corresponding Regular
Purchase being subject to the Purchase Share limitations contained in Section 2(b) hereof) and (ii) an amount equal to
(A) the Additional Accelerated Purchase Share Percentage multiplied by (B) the total number (or volume) of Ordinary Shares traded
on the Principal Market during the period on the applicable Additional Accelerated Purchase Date beginning at the Additional Accelerated
Purchase Commencement Time for such Additional Accelerated Purchase and ending at the Additional Accelerated Purchase Termination
Time for such Additional Accelerated Purchase.


 




    	-3-



    	 



    

 


(o)       “Additional
Accelerated Purchase Share Percentage” means, with respect to an Additional Accelerated Purchase made pursuant to Section
2(d) hereof, twenty percent (20%).


 


(p)       “Additional
Accelerated Purchase Share Volume Maximum” means, with respect to an Additional Accelerated Purchase made pursuant to
Section 2(d) hereof, a number of Ordinary Shares equal to (i) the number of Purchase Shares specified by the Company in
the applicable Additional Accelerated Purchase Notice as the Additional Accelerated Purchase Share Amount to be purchased by the
Investor in such Additional Accelerated Purchase, divided by (ii) the Additional Accelerated Purchase Share Percentage (to be
appropriately adjusted for any applicable reorganization, recapitalization, non-cash dividend, stock split, reverse stock split
or other similar transaction).


 


(q)       “Alternate
Adjusted Regular Purchase Share Limit” means, with respect to a Regular Purchase made pursuant to Section 2(b)
hereof, the maximum number of Purchase Shares which, taking into account the applicable per share Purchase Price therefor calculated
in accordance with this Agreement, would enable the Company to deliver to the Investor, on the applicable Purchase Date for such
Regular Purchase, a Regular Purchase Notice for a Purchase Amount equal to, or as closely approximating without exceeding, Seventy-Five
Thousand Dollars ($75,000).


 


(r)
       “Available Amount” means, initially, Ten Million Two Hundred Seventy-Five
Thousand Dollars ($10,275,000) in the aggregate, which amount shall be reduced by (i) the Initial Purchase Amount upon the purchase
of the Initial Purchase Shares by the Investor on the date hereof pursuant to Section 2(a) hereof, and (ii) the Purchase
Amount each time the Investor purchases Purchase Shares (other than the Initial Purchase Shares) pursuant to Section 2
hereof.


 


(s)       “Bankruptcy
Law” means the Israeli Companies Ordinance [New Version] 5743-1983, Title 11, U.S. Code, or any similar Israeli, federal
or state law for the relief of debtors and the rules and regulations promulgated thereunder.


 


(t)        “Business
Day” means any day on which the Principal Market is open for trading, including any day on which the Principal Market
is open for trading for a period of time less than the customary time.


 


(u)       “Closing
Sale Price” means, for any security as of any date, the last closing sale price for such security on the Principal Market
as reported by the Principal Market.


 


(v)       “Companies Law” means the Israeli Companies Law, 5759-1999, as amended,
and the rules and regulations promulgated thereunder.


 


(w)      “Confidential
Information” means any information disclosed by either party to the other party, either directly or indirectly, in writing,
orally or by inspection of tangible objects (including, without limitation, documents, prototypes, samples, plant and equipment),
which is designated as “Confidential,” “Proprietary” or some similar designation. Information communicated
orally shall be considered Confidential Information if such information is confirmed in writing as being Confidential Information
within ten (10) Business Days after the initial disclosure. Confidential Information may also include information disclosed to
a disclosing party by third parties. Confidential Information shall not, however, include any information which (i) was publicly
known and made generally available in the public domain prior to the time of disclosure by the disclosing party; (ii) becomes
publicly known and made generally available after disclosure by the disclosing party to the receiving party through no action
or inaction of the receiving party; (iii) is already in the possession of the receiving party without confidential restriction
at the time of disclosure by the disclosing party as shown by the receiving party’s files and records immediately prior
to the time of disclosure; (iv) is obtained by the receiving party from a third party without a breach of such third party’s
obligations of confidentiality; (v) is independently developed by the receiving party without use of or reference to the disclosing
party’s Confidential Information, as shown by documents and other competent evidence in the receiving party’s possession;
or (vi) is required by law to be disclosed by the receiving party, provided that the receiving party gives the disclosing party
prompt written notice of such requirement prior to such disclosure and assistance in obtaining an order protecting the information
from public disclosure.


 




    	-4-



    	 



    

 


(x)       “Custodian”
means any receiver, trustee, assignee, liquidator or similar official under any Bankruptcy Law.


 


(y)       “DTC”
means The Depository Trust Company, or any successor performing substantially the same function for the Company.


 


(z)       “DWAC
Shares” means Ordinary Shares that are (i) issued in electronic form, (ii) freely tradable and transferable and without
restriction on resale and (iii) timely credited by the Company to the Investor’s or its designee’s specified Deposit/Withdrawal
at Custodian (DWAC) account with DTC under its Fast Automated Securities Transfer (FAST) Program, or any similar program hereafter
adopted by DTC performing substantially the same function.


 


(aa)     “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated
by the SEC thereunder.


 


(bb)     “Fully
Adjusted Regular Purchase Share Limit” means, with respect to any reorganization, recapitalization, non-cash dividend,
stock split or other similar transaction from and after the date of this Agreement, the Regular Purchase Share Limit (as defined
in Section 2(b) hereof) in effect on the applicable date of determination, after giving effect to the full proportionate
adjustment thereto made pursuant to Section 2(b) hereof for or in respect of such reorganization, recapitalization, non-cash
dividend, stock split or other similar transaction.


 


(cc)     “ISA” means the Israeli Securities Authority.


 


(dd)     “Material
Adverse Effect” means any material adverse effect on (i) the enforceability of any Transaction Document, (ii) the results
of operations, assets, business or financial condition of the Company and its Subsidiaries, taken as a whole, other than any material
adverse effect that resulted exclusively from (A) any change in the United States or foreign economies or securities or financial
markets in general that does not have a disproportionate effect on the Company and its Subsidiaries, taken as a whole, (B) any
change that generally affects the industry in which the Company and its Subsidiaries operate that does not have a disproportionate
effect on the Company and its Subsidiaries, taken as a whole, (C) any change arising in connection with earthquakes, hostilities,
acts of war, sabotage or terrorism or military actions or any escalation or material worsening of any such hostilities, acts of
war, sabotage or terrorism or military actions existing as of the date hereof, (D) any action taken by the Investor, its affiliates
or its or their successors and assigns with respect to the transactions contemplated by this Agreement, (E) the effect of any
change in applicable laws or accounting rules that does not have a disproportionate effect on the Company and its Subsidiaries,
taken as a whole, or (F) any change resulting from compliance with terms of this Agreement or the consummation of the transactions
contemplated by this Agreement, or (iii) the Company’s ability to perform in any material respect on a timely basis its
obligations under any Transaction Document to be performed as of the date of determination.


 




    	-5-



    	 



    

 


(ee)     “Maturity
Date” means the first day of the month immediately following the twenty-four (24) month anniversary of the Commencement
Date.


 


(ff)       “PEA
Period” means the period commencing at 9:30 a.m., Eastern time, on the fifth (5th) Business Day immediately prior to
the filing of any post-effective amendment to the Registration Statement (as defined herein) or New Registration Statement (as
such term is defined in the Registration Rights Agreement), and ending at 9:30 a.m., Eastern time, on the Business Day immediately
following, the effective date of any post-effective amendment to the Registration Statement (as defined herein) or New Registration
Statement (as such term is defined in the Registration Rights Agreement).


 


(gg)     “Person”
means an individual or entity including but not limited to any limited liability company, a partnership, a joint venture, a corporation,
a trust, an unincorporated organization and a government or any department or agency thereof.


 


(hh)     “Principal
Market” means the OTCQB operated by the OTC Markets Group, Inc. (or any nationally recognized successor thereto); provided,
however, that in the event the Company’s Ordinary Shares are ever listed or traded on The Nasdaq Capital Market, The Nasdaq
Global Market, The Nasdaq Global Select Market, the New York Stock Exchange, the NYSE American, the NYSE Arca, the OTC Bulletin
Board, or the OTCQX operated by the OTC Markets Group, Inc. (or any nationally recognized successor to any of the foregoing),
then the “Principal Market” shall mean such other market or exchange on which the Company’s Ordinary Shares
are then listed or traded.


 


(ii)       “Purchase
Amount” means, with respect to the Initial Purchase, any Regular Purchase, any Accelerated Purchase, and any Additional
Accelerated Purchase made hereunder, as applicable, the portion of the Available Amount to be purchased by the Investor pursuant
to Section 2 hereof.


 


(jj)       “Purchase
Date” means, with respect to a Regular Purchase made pursuant to Section 2(b) hereof, the Business Day on which
the Investor receives, after 4:00 p.m., Eastern time, but prior to 5:00 p.m., Eastern time, on such Business Day, a valid Regular
Purchase Notice for such Regular Purchase in accordance with this Agreement.


 


(kk)     “Purchase
Price” means, with respect to a Regular Purchase made pursuant to Section 2(b) hereof, ninety-five percent (95%)
of the lower of: (i) the lowest Sale Price on the Purchase Date for such Regular Purchase and (ii) the arithmetic average of the
three (3) lowest Closing Sale Prices for an Ordinary Share during the fifteen (15) consecutive Business Days ending on the Business
Day immediately preceding such Purchase Date for such Regular Purchase (in each case, to be appropriately adjusted for any reorganization,
recapitalization, non-cash dividend, stock split or other similar transaction that occurs on or after the date of this Agreement).


 


(ll)       “Regular
Purchase Floor Price” means $0.02, which shall be appropriately adjusted for any reorganization, recapitalization, non-cash
dividend, stock split or other similar transaction and, effective upon the consummation of any such reorganization, recapitalization,
non-cash dividend, stock split or other similar transaction, the Regular Purchase Floor Price shall mean the lower of (i)
the adjusted price and (ii) $0.50.


 




    	-6-



    	 



    

 


(mm)   “Regular
Purchase Notice” means, with respect to a Regular Purchase pursuant to Section 2(b) hereof, an irrevocable written
notice from the Company to the Investor directing the Investor to buy a specified number of Purchase Shares (subject to the Purchase
Share limitations contained in Section 2(b) hereof) at the applicable Purchase Price for such Regular Purchase in accordance
with this Agreement.


 


(nn)     “Sale
Price” means any trade price for an Ordinary Share on the Principal Market as reported by the Principal Market.


 


(oo)    “SEC”
means the U.S. Securities and Exchange Commission.


 


(pp)     “Securities”
means, collectively, the Purchase Shares and the Commitment Shares.


 


(qq)     “Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated by the SEC thereunder.


 


(rr)      “Securities Law” means the Israeli Securities Law 5728-1968, as amended, and the rules and regulations
promulgated thereunder.


 


(ss)     “Subsidiary”
means any Person the Company wholly-owns or controls, or in which the Company, directly or indirectly, owns a majority of the
voting stock or similar voting interest, in each case that would be disclosable pursuant to Item 601(b)(21) of Regulation S-K
promulgated under the Securities Act.


 


(tt)       “Transaction
Documents” means, collectively, this Agreement and the schedules and exhibits hereto, the Registration Rights Agreement
and the schedules and exhibits thereto, and each of the other agreements, documents, certificates and instruments entered into
or furnished by the parties hereto or thereto in connection with the transactions contemplated hereby and thereby.


 


(uu)     “Transfer Agent” means Worldwide Stock Transfer, LLC, or such other Person who is then serving as the transfer
agent for the Company in respect of the Ordinary Shares.


 


(vv)     “VWAP”
means in respect of an Accelerated Purchase Date or an Additional Accelerated Purchase Date, as applicable, the volume weighted
average price of the Ordinary Shares on the Principal Market, as reported on the Principal Market.


 


2.
PURCHASE OF ORDINARY SHARES. 


 


Subject
to the terms and conditions set forth in this Agreement, the Company has the right to sell to the Investor, and the Investor has
the obligation to purchase from the Company, Purchase Shares as follows:


 


(a)       Initial
Purchase. On the date of this Agreement, upon the satisfaction of the conditions set forth in Sections 7(I) and 8(I)
hereof, the Company shall issue and sell to the Investor and the Investor shall purchase from the Company (such purchase,
the “Initial Purchase”) Three Million Four Hundred Thirty-Seven Thousand Five Hundred (3,437,500) Purchase
Shares (collectively, the “Initial Purchase Shares”) for aggregate consideration of Two Hundred Seventy-Five
Thousand Dollars ($275,000) (the “Initial Purchase Amount”).


 




    	-7-



    	 



    

 


 


(b)       Commencement
of Regular Sales of Ordinary Shares. Upon the satisfaction of all of the conditions set forth in Sections 7(II) and
8(II) hereof (the “Commencement” and the date of satisfaction of such conditions the “Commencement
Date”) and thereafter, the Company shall have the right, but not the obligation, to direct the Investor, by its delivery
to the Investor of a Regular Purchase Notice from time to time, to purchase up to Five Hundred Thousand (500,000) Purchase Shares,
subject to adjustment as set forth below in this Section 2(b) (such maximum number of Purchase Shares, as may be adjusted
from time to time, the “Regular Purchase Share Limit”), at the Purchase Price on the Purchase Date (each such
purchase a “Regular Purchase”); provided, however, that (i) the Regular Purchase Share Limit
shall be increased to Seven Hundred Fifty Thousand (750,000) Purchase Shares, if the Closing Sale Price of an Ordinary Share on
the applicable Purchase Date is not below $0.10, and (ii) the Regular Purchase Share Limit shall be increased to One Million (1,000,000)
Purchase Shares, if the Closing Sale Price of an Ordinary Share on the applicable Purchase Date is not below $0.13 (all of which
share and dollar amounts shall be appropriately proportionately adjusted for any reorganization, recapitalization, non-cash dividend,
stock split or other similar transaction; provided that if, after giving effect to the full proportionate adjustment to
the Regular Purchase Share Limit therefor, the Fully Adjusted Regular Purchase Share Limit then in effect would preclude the Company
from delivering to the Investor a Regular Purchase Notice hereunder for a Purchase Amount (calculated by multiplying (X) the number
of Purchase Shares equal to the Fully Adjusted Regular Purchase Share Limit, by (Y) the Purchase Price per Purchase Share covered
by such Regular Purchase Notice on the applicable Purchase Date therefor) equal to or greater than Seventy-Five Thousand Dollars
($75,000), the Regular Purchase Share Limit for such Regular Purchase Notice shall not be fully adjusted to equal the applicable
Fully Adjusted Regular Purchase Share Limit, but rather the Regular Purchase Share Limit for such Regular Purchase Notice shall
be adjusted to equal the applicable Alternate Adjusted Regular Purchase Share Limit as of the applicable Purchase Date for such
Regular Purchase Notice); and provided, further, however, that the Investor’s committed obligation
under any single Regular Purchase, other than any Regular Purchase with respect to which an Alternate Adjusted Regular Purchase
Share Limit shall apply, shall not exceed Five Hundred Thousand Dollars ($500,000). If the Company delivers any Regular Purchase
Notice for a Purchase Amount in excess of the limitations contained in the immediately preceding sentence, such Regular Purchase
Notice shall be void ab initio to the extent of the amount by which the number of Purchase Shares set forth in such Regular
Purchase Notice exceeds the number of Purchase Shares which the Company is permitted to include in such Purchase Notice in accordance
herewith, and the Investor shall have no obligation to purchase such excess Purchase Shares in respect of such Regular Purchase
Notice; provided, however, that the Investor shall remain obligated to purchase the number of Purchase Shares which
the Company is permitted to include in such Regular Purchase Notice. The Company may deliver a Regular Purchase Notice to the
Investor as often as every Business Day, so long as (i) the Closing Sale Price of an Ordinary Share on such Business Day is not
less than the Regular Purchase Floor Price and (ii) all Purchase Shares subject to all prior Regular Purchases have theretofore
been received by the Investor as DWAC Shares in accordance with this Agreement. Notwithstanding the foregoing, the Company shall
not deliver any Regular Purchase Notices to the Investor during the PEA Period.


 


(c)       Accelerated
Purchases. Subject to the terms and conditions of this Agreement, from and after the Commencement Date, in addition to purchases
of Purchase Shares as described in Section 2(a) and Section 2(b) above, the Company shall also have the right, but
not the obligation, to direct the Investor, by its delivery to the Investor of an Accelerated Purchase Notice from time to time
in accordance with this Agreement, to purchase the applicable Accelerated Purchase Share Amount at the Accelerated Purchase Price
on the Accelerated Purchase Date therefor in accordance with this Agreement (each such purchase, an “Accelerated Purchase”).
The Company may deliver an Accelerated Purchase Notice to the Investor only on a Purchase Date on which (i) the Company also properly
submitted a Regular Purchase Notice providing for a Regular Purchase of a number of Purchase Shares not less than the Regular
Purchase Share Limit then in effect on such Purchase Date in accordance with this Agreement (including, without limitation, giving
effect to any automatic increase to the Regular Purchase Share Limit as a result of the Closing Sale Price of an Ordinary Share
exceeding certain thresholds set forth in Section 2(b) above on such Purchase Date and any other adjustments to the Regular
Purchase Share Limit, in each case pursuant to Section 2(b) above) and (ii) the Closing Sale Price of an Ordinary Share
is not less than the Accelerated Purchase Floor Price. If the Company delivers any Accelerated Purchase Notice directing the Investor
to purchase an amount of Purchase Shares that exceeds the Accelerated Purchase Share Amount that the Company is then permitted
to include in such Accelerated Purchase Notice, such Accelerated Purchase Notice shall be void ab initio to the extent
of the amount by which the number of Purchase Shares set forth in such Accelerated Purchase Notice exceeds the Accelerated Purchase
Share Amount that the Company is then permitted to include in such Accelerated Purchase Notice (which shall be confirmed in an
Accelerated Purchase Confirmation), and the Investor shall have no obligation to purchase such excess Purchase Shares in respect
of such Accelerated Purchase Notice; provided, however, that the Investor shall remain obligated to purchase the
Accelerated Purchase Share Amount which the Company is permitted to include in such Accelerated Purchase Notice. Within one (1)
Business Day after completion of each Accelerated Purchase Date for an Accelerated Purchase, the Investor shall provide to the
Company a written confirmation of such Accelerated Purchase setting forth the applicable Accelerated Purchase Share Amount and
Accelerated Purchase Price for such Accelerated Purchase (each, an “Accelerated Purchase Confirmation”). Notwithstanding
the foregoing, the Company shall not deliver any Accelerated Purchase Notices to the Investor during the PEA Period.


 




    	-8-



    	 



    

 


(d)       Additional
Accelerated Purchases. Subject to the terms and conditions of this Agreement, from and after the Commencement Date, in addition
to purchases of Purchase Shares as described in Section 2(a), Section 2(b) and Section 2(c) above, the Company
shall also have the right, but not the obligation, to direct the Investor, by its timely delivery to the Investor of an Additional
Accelerated Purchase Notice on an Additional Accelerated Purchase Date in accordance with this Agreement, to purchase the applicable
Additional Accelerated Purchase Share Amount at the applicable Additional Accelerated Purchase Price therefor in accordance with
this Agreement (each such purchase, an “Additional Accelerated Purchase”). The Company may deliver multiple
Additional Accelerated Purchase Notices to the Investor on an Additional Accelerated Purchase Date; provided, however,
that the Company may deliver an Additional Accelerated Purchase Notice to the Investor only (i) on a Business Day that is also
the Accelerated Purchase Date for an Accelerated Purchase with respect to which the Company properly submitted to the Investor
an Accelerated Purchase Notice in accordance with this Agreement on the applicable Purchase Date for a Regular Purchase of a number
of Purchase Shares not less than the Regular Purchase Share Limit then in effect in accordance with this Agreement (including,
without limitation, giving effect to any automatic increase to the Regular Purchase Share Limit as a result of the Closing Sale
Price of an Ordinary Share exceeding certain thresholds set forth in Section 2(b) above on such Purchase Date and any other
adjustments to the Regular Purchase Share Limit, in each case pursuant to Section 2(b) above), (ii) if the Closing Sale
Price of an Ordinary Share on the Business Day immediately preceding the Business Day on which such Additional Accelerated Purchase
Notice is delivered is not less than the Additional Accelerated Purchase Floor Price, and (iii) if all Purchase Shares subject
to all prior Regular Purchases, Accelerated Purchases and Additional Accelerated Purchases, including, without limitation, those
that have been effected on the same Business Day as the applicable Additional Accelerated Purchase Date with respect to which
the applicable Additional Accelerated Purchase relates, in each case have theretofore been received by the Investor as DWAC Shares
in accordance with this Agreement. If the Company delivers any Additional Accelerated Purchase Notice directing the Investor to
purchase an amount of Purchase Shares that exceeds the Additional Accelerated Purchase Share Amount that the Company is then permitted
to include in such Additional Accelerated Purchase Notice, such Additional Accelerated Purchase Notice shall be void ab initio
to the extent of the amount by which the number of Purchase Shares set forth in such Additional Accelerated Purchase Notice
exceeds the Additional Accelerated Purchase Share Amount that the Company is then permitted to include in such Additional Accelerated
Purchase Notice (which shall be confirmed in an Additional Accelerated Purchase Confirmation), and the Investor shall have no
obligation to purchase such excess Purchase Shares in respect of such Additional Accelerated Purchase Notice; provided,
however, that the Investor shall remain obligated to purchase the Additional Accelerated Purchase Share Amount which the
Company is permitted to include in such Additional Accelerated Purchase Notice. Within one (1) Business Day after completion of
each Additional Accelerated Purchase Date, the Investor will provide to the Company a written confirmation of each Additional
Accelerated Purchase on such Additional Accelerated Purchase Date setting forth the applicable Additional Accelerated Purchase
Share Amount and Additional Accelerated Purchase Price for each such Additional Accelerated Purchase on such Additional Accelerated
Purchase Date (each, an “Additional Accelerated Purchase Confirmation”). Notwithstanding the foregoing, the
Company shall not deliver any Additional Accelerated Purchase Notices to the Investor during the PEA Period.


 




    	-9-



    	 



    

 


(e)      
Payment for Purchase Shares. For the Initial Purchase and each Regular Purchase, the Investor shall pay to the Company
an amount equal to the Purchase Amount with respect to such Regular Purchase and Initial Purchase, respectively, as full payment
for such Purchase Shares via wire transfer of immediately available funds on the same Business Day that the Investor receives
such Purchase Shares, if such Purchase Shares are received by the Investor before 1:00 p.m., Eastern time, or, if such Purchase
Shares are received by the Investor after 1:00 p.m., Eastern time, the next Business Day. For each Accelerated Purchase and each
Additional Accelerated Purchase, the Investor shall pay to the Company an amount equal to the Purchase Amount with respect to
such Accelerated Purchase and Additional Accelerated Purchase, respectively, as full payment for such Purchase Shares via wire
transfer of immediately available funds on the second Business Day following the date that the Investor receives such Purchase
Shares. If the Company or the Transfer Agent shall fail for any reason or for no reason to electronically transfer any Purchase
Shares as DWAC Shares in respect of a Regular Purchase, an Accelerated Purchase or an Additional Accelerated Purchase (as applicable)
within two (2) Business Days following the receipt by the Company of the Purchase Price, Accelerated Purchase Price and Additional
Accelerated Purchase Price, respectively, therefor in compliance with this Section 2(e), and if on or after such Business
Day the Investor purchases (in an open market transaction or otherwise) Ordinary Shares to deliver in satisfaction of a sale by
the Investor of such Purchase Shares that the Investor anticipated receiving from the Company in respect of such Regular Purchase,
Accelerated Purchase or Additional Accelerated Purchase (as applicable), then the Company shall, within two (2) Business Days
after the Investor’s request, either (i) pay cash to the Investor in an amount equal to the Investor’s total purchase
price (including brokerage commissions, if any) for the Ordinary Shares so purchased (the “Cover Price”), at
which point the Company’s obligation to deliver such Purchase Shares as DWAC Shares shall terminate, or (ii) promptly honor
its obligation to deliver to the Investor such Purchase Shares as DWAC Shares and pay cash to the Investor in an amount equal
to the excess (if any) of the Cover Price over the total Purchase Amount paid by the Investor pursuant to this Agreement for all
of the Purchase Shares to be purchased by the Investor in connection with such Regular Purchase, Accelerated Purchase and Additional
Accelerated Purchase (as applicable). The Company shall not issue any fraction of an Ordinary Share upon the Initial Purchase
or any Regular Purchase, Accelerated Purchase or Additional Accelerated Purchase. If the issuance would result in the issuance
of a fraction of an Ordinary Share, the Company shall round such fraction of an Ordinary Share up or down to the nearest whole
share. All payments made under this Agreement shall be made in lawful money of the United States of America or wire transfer of
immediately available funds to such account as the Company may from time to time designate by written notice in accordance with
the provisions of this Agreement. Whenever any amount expressed to be due by the terms of this Agreement is due on any day that
is not a Business Day, the same shall instead be due on the next succeeding day that is a Business Day.


 


(f)       Beneficial
Ownership Limitation. Notwithstanding anything to the contrary contained in this Agreement, the Company shall not issue or
sell, and the Investor shall not purchase or acquire, any Ordinary Shares under this Agreement which, when aggregated with all
other Ordinary Shares then beneficially owned by the Investor and its affiliates (as calculated pursuant to Section 13(d) of the
Exchange Act and Rule 13d-3 promulgated thereunder), would result in the beneficial ownership by the Investor of more than 4.99%
of the outstanding Ordinary Shares (the “Beneficial Ownership Limitation”). Upon the written or oral request
of the Investor, the Company shall promptly (but not later than 24 hours) confirm orally or in writing to the Investor the number
of Ordinary Shares then outstanding. The Investor and the Company shall each cooperate in good faith in the determinations required
hereby and the application hereof. The Investor’s written certification to the Company of the applicability of the Beneficial
Ownership Limitation, and the resulting effect thereof hereunder at any time, shall be conclusive with respect to the applicability
thereof and such result absent manifest error.


 




    	-10-



    	 



    

 


3.        INVESTOR’S
REPRESENTATIONS AND WARRANTIES.


 


The
Investor represents and warrants to the Company that as of the date hereof and as of the Commencement Date:


 


(a)       Investment
Purpose. The Investor is acquiring the Securities as principal for its own account and not with a view to or for distributing
or reselling such Securities or any part thereof in violation of the Securities Act or any applicable state securities law, has
no present intention of distributing any of such Securities in violation of the Securities Act or any applicable state securities
law and has no direct or indirect arrangement or understandings with any other Persons to distribute or regarding the distribution
of such Securities in violation of the Securities Act or any applicable state securities law (this representation and warranty
not limiting the Investor’s right to sell the Securities at any time pursuant to the Registration Statement described herein
or otherwise in compliance with applicable federal and state securities laws). The Investor is acquiring the Securities hereunder
in the ordinary course of its business.


 


(b)       Accredited
Investor Status. The Investor is an “accredited investor” as that term is defined in Rule 501(a)(3) of Regulation
D promulgated under the Securities Act.


 


(c)       Reliance
on Exemptions. The Investor understands that the Securities are being offered and sold to it in reliance on specific exemptions
from the registration requirements of United States federal and state securities laws and that the Company is relying in part
upon the truth and accuracy of, and the Investor’s compliance with, the representations, warranties, agreements, acknowledgments
and understandings of the Investor set forth herein in order to determine the availability of such exemptions and the eligibility
of the Investor to acquire the Securities.


 


(d)       Information.
The Investor understands that its investment in the Securities involves a high degree of risk. The Investor (i) is able to bear
the economic risk of an investment in the Securities including a total loss thereof, (ii) has such knowledge and experience in
financial and business matters that it is capable of evaluating the merits and risks of the proposed investment in the Securities
and (iii) has had an opportunity to ask questions of and receive answers from the officers of the Company concerning the financial
condition and business of the Company and others matters related to an investment in the Securities. Neither such inquiries nor
any other due diligence investigations conducted by the Investor or its representatives shall modify, amend or affect the Investor’s
right to rely on the Company’s representations and warranties contained in Section 4 below. The Investor has sought such accounting,
legal and tax advice from its own independent advisors as it has considered necessary to make an informed investment decision
with respect to its acquisition of the Securities and is not relying on any accounting, legal, tax or other advise from the Company,
its officers, directors, representatives or advisors.


 


(e)       No
Governmental Review. The Investor understands that no Israeli, U.S. federal or state agency or any other domestic or foreign
government or governmental agency has passed on or made any recommendation or endorsement of the Securities or the fairness or
suitability of an investment in the Securities nor have such authorities passed upon or endorsed the merits of the offering of
the Securities.


 




    	-11-



    	 



    

 


(f)       Transfer
or Sale. The Investor understands that (i) the Securities may not be offered for sale, sold, assigned or transferred unless
(A) registered pursuant to the Securities Act or (B) an exemption exists permitting such Securities to be sold, assigned or transferred
without such registration; (ii) any sale of the Securities made in reliance on Rule 144 may be made only in accordance with the
terms of Rule 144 and further, if Rule 144 is not applicable, any resale of the Securities under circumstances in which the seller
(or the Person through whom the sale is made) may be deemed to be an underwriter (as that term is defined in the Securities Act)
may require compliance with some other exemption under the Securities Act or the rules and regulations of the SEC thereunder.


 


(g)       Validity;
Enforcement. This Agreement has been duly and validly authorized, executed and delivered on behalf of the Investor and is
a valid and binding agreement of the Investor enforceable against the Investor in accordance with its terms, subject as to enforceability
to general principles of equity and to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar
laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies.


 


(h)       Residency.
The Investor is a resident of the State of Illinois.


 


(i)       No
Short Selling. The Investor represents and warrants to the Company that at no time prior to the date of this Agreement has
any of the Investor, its agents, representatives or affiliates engaged in or effected, in any manner whatsoever, directly or indirectly,
any (i) “short sale” (as such term is defined in Rule 200 of Regulation SHO of the Exchange Act) of the Ordinary Shares
or (ii) hedging transaction, which establishes a net short position with respect to the Ordinary Shares.


 


4.        REPRESENTATIONS
AND WARRANTIES OF THE COMPANY.


 


The
Company represents and warrants to the Investor that, except as set forth in the disclosure schedules attached hereto, which exceptions
shall be deemed to be a part of the representations and warranties made hereunder, as of the date hereof and as of the Commencement
Date:


 


(a)       Organization
and Qualification. The Company and each of its Subsidiaries is an entity duly incorporated or otherwise organized, validly
existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite corporate
power and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the
Company nor any of its Subsidiaries is in violation or default of any of the provisions of its respective certificate or articles
of incorporation or association, or other organizational or charter documents. Each of the Company and its Subsidiaries is duly
qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the
nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so
qualified or in good standing, as the case may be, could not have or reasonably be expected to result in a Material Adverse Effect
and no proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or
curtail such power and authority or qualification. The Company has no Subsidiaries except as set forth in the Company’s
Annual Report on Form 20-F for the year ended December 31, 2019.


 


(b)       Authorization;
Enforcement; Validity. (i) The Company has the requisite corporate power and authority to enter into and perform its obligations
under this Agreement, the Registration Rights Agreement and each of the other Transaction Documents to which it is a party, and
to issue the Securities in accordance with the terms hereof and thereof, (ii) the execution and delivery of the Transaction Documents
by the Company and the consummation by it of the transactions contemplated hereby and thereby, including without limitation, the
issuance of the Commitment Shares (as defined below in Section 5(e)), the issuance and sale of the Initial Purchase Shares,
and the reservation for issuance and the issuance of the Purchase Shares other than the Initial Purchase Shares issuable under
this Agreement, have been duly authorized by the Company’s Board of Directors and no further consent or authorization is required
by the Company, its Board of Directors or its stockholders (except as provided in this Agreement), (iii) each of this Agreement
and the Registration Rights Agreement has been, and each other Transaction Document shall be on the Commencement Date, duly executed
and delivered by the Company and (iv) each of this Agreement and the Registration Rights Agreement constitutes, and each other
Transaction Document upon its execution on behalf of the Company, shall constitute, the valid and binding obligations of the Company
enforceable against the Company in accordance with their terms, except as such enforceability may be limited by general principles
of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting
generally, the enforcement of creditors’ rights and remedies. The Board of Directors has approved the resolutions (the “Signing
Resolutions”) substantially in the form as set forth as Exhibit C attached hereto to authorize this Agreement,
the Registration Rights Agreement and the transactions contemplated hereby. The Signing Resolutions are valid, in full force and
effect and have not been modified or supplemented in any respect. The Company has delivered to the Investor a certified copy of
the Signing Resolutions. No other approvals or consents of the Board of Directors or the Company’s shareholders is necessary
under applicable laws and the Company’s Articles of Association to authorize the execution and delivery of this Agreement,
the Registration Rights Agreement or any of the transactions contemplated hereby, including, but not limited to, the issuance
of the Commitment Shares and the issuance and sale of the Purchase Shares.


 




    	-12-



    	 



    

 


(c)       Capitalization.
As of the date hereof, the authorized capital stock of the Company is set forth in the Company’s Annual Report on Form 20-F
for the year ended December 31, 2019. Except as disclosed in the SEC Documents (as defined below), (i) no shares of the Company’s
capital stock are subject to preemptive rights or any other similar rights or any liens or encumbrances suffered or permitted
by the Company, (ii) there are no outstanding debt securities, (iii) there are no outstanding options, warrants, scrip, rights
to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into, any shares
of capital stock of the Company or any of its Subsidiaries, or contracts, commitments, understandings or arrangements by which
the Company or any of its Subsidiaries is or may become bound to issue additional shares of capital stock of the Company or any
of its Subsidiaries or options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating
to, or securities or rights convertible into, any shares of capital stock of the Company or any of its Subsidiaries, (iv) there
are no agreements or arrangements under which the Company or any of its Subsidiaries is obligated to register the sale of any
of their securities under the Securities Act (except the Registration Rights Agreement), (v) there are no outstanding securities
or instruments of the Company or any of its Subsidiaries which contain any redemption or similar provisions, and there are no
contracts, commitments, understandings or arrangements by which the Company or any of its Subsidiaries is or may become bound
to redeem a security of the Company or any of its Subsidiaries, (vi) there are no securities or instruments containing anti-dilution
or similar provisions that will be triggered by the issuance of the Securities as described in this Agreement and (vii) the Company
does not have any stock appreciation rights or “phantom stock” plans or agreements or any similar plan or agreement.
The Company has furnished to the Investor true and correct copies of the Company’s Amended and Restated Articles of Association,
as amended and as in effect on the date hereof (the “Articles of Association”), and summaries of the material
terms of all securities convertible into or exercisable for Ordinary Shares, if any, and copies of any documents containing the
material rights of the holders thereof in respect thereto that are not disclosed in the SEC Documents.


 


(d)       Issuance
of Securities. Upon issuance and payment therefor in accordance with the terms and conditions of this Agreement, the Purchase
Shares (including, without limitation, the Initial Purchase Shares) shall be validly issued, fully paid and nonassessable and
free from all taxes, liens, charges, restrictions (other than such restrictions on transfer arising under the Securities Act prior
to the effective date of the Registration Statement registering the resale thereof by the Investor under the Securities Act),
rights of first refusal and preemptive rights with respect to the issue thereof, with the holders being entitled to all rights
accorded to a holder of Ordinary Shares under the Articles of Association and the Companies Law. Upon issuance in accordance with
the terms and conditions of this Agreement, the Commitment Shares (as defined below in Section 5(e)) shall be validly issued,
fully paid and nonassessable and free from all taxes, liens, charges, restrictions (other than such restrictions on transfer arising
under the Securities Act prior to the effective date of the Registration Statement registering the resale thereof by the Investor
under the Securities Act), rights of first refusal and preemptive rights with respect to the issue thereof, with the holders being
entitled to all rights accorded to a holder of Ordinary Shares under the Articles of Association and the Companies Law. 200,000,000
Ordinary Shares have been duly authorized and reserved for issuance upon purchase under this Agreement as Purchase Shares (other
than the Initial Purchase Shares).


 




    	-13-



    	 



    

 


(e)       No
Conflicts. The execution, delivery and performance of the Transaction Documents by the Company and the consummation by the
Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Commitment Shares
and the issuance and sale of the Initial Purchase Shares, and the reservation for issuance and issuance of the Purchase Shares
other than the Initial Purchase Shares) will not (i) result in a violation of the Articles of Association or (ii) conflict with,
or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others
any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Company
or any of its Subsidiaries is a party, or result in a violation of any law, rule, regulation, order, judgment or decree (including
Israeli and U.S. federal and state securities laws and regulations, and the rules and regulations of the Principal Market applicable
to the Company or any of its Subsidiaries) or by which any property or asset of the Company or any of its Subsidiaries is bound
or affected, except in the case of conflicts, defaults, terminations, amendments, accelerations, cancellations and violations
under clause (ii), which could not reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any
of its Subsidiaries is in violation of its Articles of Association (or other similar organizational documents), or is in violation
of any term of, or is in default under, any contract, agreement, mortgage, indebtedness, indenture, instrument, judgment, decree
or order or any statute, rule or regulation applicable to the Company or its Subsidiaries, except for such conflicts, defaults,
terminations or amendments which could not reasonably be expected to have a Material Adverse Effect. The business of the Company
and its Subsidiaries is not being conducted, and shall not be conducted, in violation of any law, ordinance or regulation of any
Israeli or U.S. federal or state governmental entity, except for possible violations, the sanctions for which either individually
or in the aggregate could not reasonably be expected to have a Material Adverse Effect. Except as specifically contemplated by
this Agreement and as required under the Securities Law, the Securities Act or applicable state securities laws, the Company is
not required to obtain any consent, authorization or order of, or make any filing or registration with, any court or governmental
agency or any regulatory or self-regulatory agency in order for it to execute, deliver or perform any of its obligations under
or contemplated by the Transaction Documents in accordance with the terms hereof or thereof. Except as set forth elsewhere in
this Agreement, all consents, authorizations, orders, filings and registrations which the Company is required to obtain pursuant
to the preceding sentence shall be obtained or effected on or prior to the Commencement Date.


 


(f)       SEC
Documents; Financial Statements. The Company has filed all reports, schedules, forms, statements and other documents required
to be filed by the Company under the Securities Law, the Securities Act and the Exchange Act, including pursuant to Section 13(a)
or 15(d) thereof, for the twelve months preceding the date hereof (or such shorter period as the Company was required by law or
regulation to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference
therein, being collectively referred to herein as the “SEC Documents”) on a timely basis or has received a
valid extension of such time of filing and has filed any such SEC Documents prior to the expiration of any such extension. As
of their respective dates, the SEC Documents complied in all material respects with the requirements of the Securities Act and
the Exchange Act, as applicable, except that the Company’s Form 20-F filed with the SEC on June 15, 2020 did not include
financial statements for the year ended December 31, 2017. None of the SEC Documents, when filed, contained any untrue statement
of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading. The financial statements of the Company
included in the SEC Documents comply in all material respects with applicable accounting requirements and the rules and regulations
of the SEC with respect thereto as in effect at the time of filing. Such financial statements have been prepared in accordance
with United States generally accepted accounting principles applied on a consistent basis during the periods involved (“GAAP”),
except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements
may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company
and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods
then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments. Except as set forth
in the SEC Documents, the Company has received no notices or correspondence from the SEC for the one year preceding the date hereof.
The SEC has not commenced any enforcement proceedings against the Company or any of its Subsidiaries.


 




    	-14-



    	 



    

 


(g)       Absence
of Certain Changes. Except as disclosed in the SEC Documents, since December 31, 2019, there has been no material adverse
change in the business, properties, operations, financial condition or results of operations of the Company or its Subsidiaries.
The Company has not taken any steps, and does not currently expect to take any steps, to seek protection pursuant to any Bankruptcy
Law nor does the Company or any of its Subsidiaries have any knowledge or reason to believe that its creditors intend to initiate
involuntary bankruptcy or insolvency proceedings. The Company is financially solvent and is generally able to pay its debts as
they become due.


 


(h)       Absence
of Litigation. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government
agency, self-regulatory organization or body pending or, to the knowledge of the Company or any of its Subsidiaries, threatened
against or affecting the Company, the Ordinary Shares or any of the Company’s or its Subsidiaries’ officers or directors in their
capacities as such, which could reasonably be expected to have a Material Adverse Effect.


 


(i)        Acknowledgment
Regarding Investor’s Status. The Company acknowledges and agrees that the Investor is acting solely in the capacity of arm’s
length purchaser with respect to the Transaction Documents and the transactions contemplated hereby and thereby. The Company further
acknowledges that the Investor is not acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with
respect to the Transaction Documents and the transactions contemplated hereby and thereby and any advice given by the Investor
or any of its representatives or agents in connection with the Transaction Documents and the transactions contemplated hereby
and thereby is merely incidental to the Investor’s purchase of the Securities. The Company further represents to the Investor
that the Company’s decision to enter into the Transaction Documents has been based solely on the independent evaluation by the
Company and its representatives and advisors.


 


(j)        No
General Solicitation; No Integrated Offering. Neither the Company, nor any of its affiliates, nor any Person acting on its
or their behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D under
the Securities Act) in connection with the offer or sale of the Securities. Neither the Company, nor or any of its affiliates,
nor any Person acting on their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers
to buy any security, under circumstances that would require registration of the offer and sale of any of the Securities under
the Securities Act, whether through integration with prior offerings or otherwise, or cause this offering of the Securities to
be integrated with prior offerings by the Company in a manner that would require stockholder approval pursuant to the Companies
Law or the rules of the Principal Market on which any of the securities of the Company are listed or designated. The issuance
and sale of the Securities hereunder does not contravene the rules and regulations of the Principal Market.


 




    	-15-



    	 



    

 


(k)       Intellectual
Property Rights. The Company and its Subsidiaries own or possess adequate rights or licenses to use all material trademarks,
trade names, service marks, service mark registrations, service names, patents, patent rights, copyrights, inventions, licenses,
approvals, governmental authorizations, trade secrets and rights necessary to conduct their respective businesses as now conducted.
None of the Company’s material trademarks, trade names, service marks, service mark registrations, service names, patents, patent
rights, copyrights, inventions, licenses, approvals, government authorizations, trade secrets or other intellectual property rights
have expired or terminated, or, by the terms and conditions thereof, could expire or terminate within two years from the date
of this Agreement. The Company and its Subsidiaries do not have any knowledge of any infringement by the Company or its Subsidiaries
of any material trademark, trade name rights, patents, patent rights, copyrights, inventions, licenses, service names, service
marks, service mark registrations, trade secret or other similar rights of others, or of any such development of similar or identical
trade secrets or technical information by others, and there is no claim, action or proceeding being made or brought against, or
to the Company’s knowledge, being threatened against, the Company or its Subsidiaries regarding trademark, trade name, patents,
patent rights, invention, copyright, license, service names, service marks, service mark registrations, trade secret or other
infringement, which could reasonably be expected to have a Material Adverse Effect.


 


(l)        Environmental
Laws. The Company and its Subsidiaries (i) are in compliance with any and all applicable foreign, federal, state and local
laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or
wastes, pollutants or contaminants (“Environmental Laws”), (ii) have received all permits, licenses or other
approvals required of them under applicable Environmental Laws to conduct their respective businesses and (iii) are in compliance
with all terms and conditions of any such permit, license or approval, except where, in each of the three foregoing clauses, the
failure to so comply could not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.


 


(m)      Title.
The Company and its Subsidiaries have good and marketable title in fee simple to all real property owned by them and good and
marketable title in all personal property owned by them that is material to the business of the Company and its Subsidiaries,
in each case free and clear of all liens, encumbrances and defects (“Liens”) and, except for Liens as do not
materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such
property by the Company and its Subsidiaries and Liens for the payment of federal, state or other taxes, the payment of which
is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and its Subsidiaries
are held by them under valid, subsisting and enforceable leases with which the Company and its Subsidiaries are in compliance
with such exceptions as are not material and do not interfere with the use made and proposed to be made of such property and buildings
by the Company and its Subsidiaries.


 


(n)       Insurance.
The Company and each of its Subsidiaries are insured by insurers of recognized financial responsibility against such losses and
risks and in such amounts as management of the Company believes to be prudent and customary in the businesses in which the Company
and its Subsidiaries are engaged. Neither the Company nor any such Subsidiary has been refused any insurance coverage sought or
applied for and neither the Company nor any such Subsidiary has any reason to believe that it will not be able to renew its existing
insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to
continue its business at a cost that would not materially and adversely affect the condition, financial or otherwise, or the earnings,
business or operations of the Company and its Subsidiaries, taken as a whole.


 




    	-16-



    	 



    

 


(o)       Regulatory
Permits. The Company and its Subsidiaries possess such valid and current certificates, authorizations, exemptions, approvals,
clearances or permits required by state, federal or foreign regulatory agencies or bodies to conduct their respective businesses
as currently conducted and as described in the SEC Documents (“Permits”). Neither the Company nor any of its
Subsidiaries is in violation of, or in default under, any of the Permits or has received any notice of proceedings relating to
the revocation or modification of, or non-compliance with, any such certificate, authorization or permit except where such revocation
or modification would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.


 


(p)       Tax
Status. (i) The Company has no liability of any nature, accrued or contingent, including without limitation, liabilities for
Israeli taxes or any other foreign taxes or any penalties, interest, and additions to taxes or any liabilities to customers or
suppliers, other than liabilities incurred in the ordinary course of business and has paid or fully provided in its books of account
for all taxation for which it has or may hereafter become liable or accountable in the period from the date of its incorporation;
(ii) the Company has at all times and within the requisite time limits, fully and accurately observed, performed and complied
with all obligations and conditions imposed on it, or to which any claim deduction, allowance or relief made, claimed by or afforded
to it was made subject under any legislation relating to taxation; (iii) The Company is not aware of any circumstances which will
or may, whether by lapse of time or the issue of any notice of assessment or otherwise, give rise to any dispute with any relevant
taxation authority in relation to its liability or accountability for taxation, any claim made by it, any relief, deduction, or
allowance afforded to it, or in relation to the status or character of the Company under or for the purpose of any provision of
any legislation relating to taxation; (iv) the Company has never had any tax deficiency proposed or assessed against it and has
not executed any waiver of any statute of limitations on the assessment or collection of any tax or governmental charge; (v) none
of the Company’s income tax returns have ever been audited by governmental authorities; and (vi) the Company has withheld
or collected from each payment made to each of its employees, the amount of all taxes required to be withheld or collected therefrom,
and has paid the same to the proper tax receiving officers or authorized depositories.


 


(q)       Transactions
With Affiliates. Except as set forth in the SEC Documents, none of the officers or directors of the Company and, to the knowledge
of the Company, none of the employees of the Company is presently a party to any transaction with the Company or any Subsidiary
(other than for services as employees, officers and directors), including any contract, agreement or other arrangement providing
for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring
payments to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer,
director, or any such employee has a substantial interest or is an officer, director, trustee or partner, in each case in excess
of $120,000 other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred
on behalf of the Company and (iii) other employee benefits, including stock option agreements under any stock option plan of the
Company.


 


(r)        No
Application of Takeover Protections. Subject to the Investor’s compliance with the terms of this Agreement, there is
no control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other
similar anti-takeover provision under the Articles of Association or the laws of Israel which is or could become applicable to
the Investor as a result of the transactions contemplated by this Agreement, including, without limitation, the Company’s
issuance of the Securities and the Investor’s ownership of the Securities.


 




    	-17-



    	 



    

 


(s)       
Disclosure. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction
Documents that will be timely publicly disclosed by the Company, the Company confirms that neither it nor any other Person acting
on its behalf has provided the Investor or its agents or counsel with any information that it believes constitutes or might constitute
material, non-public information which is not otherwise disclosed in the Registration Statement or the SEC Documents. The Company
understands and confirms that the Investor will rely on the foregoing representation in effecting purchases and sales of securities
of the Company. All of the disclosure furnished by or on behalf of the Company to the Investor regarding the Company, its business
and the transactions contemplated hereby, including the disclosure schedules to this Agreement, is true and correct and does not
contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made
therein, in light of the circumstances under which they were made, not misleading. The press releases disseminated by the Company
during the twelve months preceding the date of this Agreement are true and correct in all material respects. The Company acknowledges
and agrees that the Investor neither makes nor has made any representations or warranties with respect to the transactions contemplated
hereby other than those specifically set forth in Section 3 hereof.


 


(t)       Foreign
Corrupt Practices. Neither the Company, nor to the knowledge of the Company, any agent or other Person acting on behalf of
the Company, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful
expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials
or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully
any contribution made by the Company (or made by any Person acting on its behalf of which the Company is aware) which is in violation
of law, or (iv) violated in any material respect any provision of the Foreign Corrupt Practices Act of 1977, as amended.


 


(u)       DTC
Eligibility. The Company, through the Transfer Agent, currently participates in the DTC Fast Automated Securities Transfer
(FAST) Program and the Ordinary Shares can be transferred electronically to third parties via the DTC Fast Automated Securities
Transfer (FAST) Program.


 


(v)       Sarbanes-Oxley.
The Company is in compliance in all material respects with all provisions of the Sarbanes-Oxley Act of 2002, as amended, which
are applicable to it as of the date hereof.


 


(w)       Certain
Fees. No brokerage or finder’s fees or commissions are or will be payable by the Company to any broker, financial advisor
or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated
by the Transaction Documents. The Investor shall have no obligation with respect to any fees or with respect to any claims made
by or on behalf of other Persons for fees of a type contemplated in this Section 4(w) that may be due in connection with
the transactions contemplated by the Transaction Documents.


 


(x)       Investment
Company. The Company is not, and immediately after receipt of payment for the Securities will not be, an “investment
company” within the meaning of the Investment Company Act of 1940, as amended.


 


(y)       Listing
and Maintenance Requirements. The Ordinary Shares are registered pursuant to Section 12(b), 12(g) or 15(d) of the Exchange
Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the
registration of the Ordinary Shares pursuant to the Exchange Act nor has the Company received any notification that the SEC is
currently contemplating terminating such registration. The Company has not, in the twelve (12) months preceding the date hereof,
received any notice from any Person to the effect that the Company is not in compliance with the listing or maintenance requirements
of the Principal Market. The Company is, and has no reason to believe that it will not in the foreseeable future continue to be,
in compliance with all such listing and maintenance requirements. The Principal Market has not commenced any delisting proceedings
against the Company.


 




    	-18-



    	 



    

 


(z)       Accountants.
Fahn Kanne & Co. Grant Thornton Israel, which has expressed its opinion with respect to the financial statements (which term
as used in this Agreement includes the related notes thereto) filed with the SEC as a part of the Company’s annual report
on Form 20-F for the year ended December 31, 2019, is (i) an independent registered public accounting firm as required by the
Securities Act, the Exchange Act and the rules of the PCAOB, (ii) in compliance with the applicable requirements relating to the
qualification of accountants under Rule 2-01 of Regulation S-X under the Securities Act, (iii) a registered public accounting
firm as defined by the PCAOB whose registration has not been suspended or revoked and who has not requested such registration
to be withdrawn and (iv) an independent qualified public accountant qualified under the applicable provisions of the Companies
Law, the Securities Law and any ordinances promulgated thereunder.


 


(aa)     No
Market Manipulation. The Company has not, and to its knowledge no Person acting on its behalf has, (i) taken, directly or
indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the
Company to facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for
soliciting purchases of, any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another
to purchase any other securities of the Company.


 


(bb)     Shell
Company Status. The Company is not currently, and has never been, an issuer identified in Rule 144(i)(1) under the Securities
Act.


 


(cc)     Foreign
Private Issuer. The Company is a “foreign private issuer” within the meaning of Rule 405 under the Securities
Act.


 


(dd)     PFIC
Status. As of December 31, 2019, the Company believes that it was not a “passive foreign investment company,”
as such term is defined in the Internal Revenue Code of 1986, as amended (the “Code”). Neither the Company
nor any Subsidiary of the Company is, and, after giving effect to the offering, issuance and sale of the Securities to the Investor
and the application of the proceeds thereof, none of them will be, a “controlled foreign corporation” as defined by
the Code.


 


(ee)     Submission
to Jurisdiction. The Company has the power to submit, and pursuant to Section 12(a) of this Agreement, has legally, validly,
effectively and irrevocably submitted, to the personal jurisdiction of each United States federal court and Delaware state court
located in the State of Delaware (each, an “Delaware Court”), and the Company has the power to designate, appoint
and authorize, and pursuant to Section 12(a) of this Agreement, has legally, validly, effectively and irrevocably designated,
appointed and authorized the an agent for service of process in any action arising out of or relating to the Securities, this
Agreement or any of the other Transaction Documents or any of the transactions contemplated hereby or thereby in any Delaware
Court, and service of process effected on such authorized agent will be effective to confer valid personal jurisdiction over the
Company as provided in Section 12(a) hereof.


 


(ff)       No
Rights of Immunity. Except as provided by laws or statutes generally applicable to transactions of the type described in this
Agreement, neither the Company nor any of its respective properties, assets or revenues has any right of immunity under Israeli,
Delaware or United States laws, from any legal action, suit or proceeding, from the giving of any relief in any such legal action,
suit or proceeding, from set-off or counterclaim, from the jurisdiction of any Israeli, Delaware or United States federal court,
from service of process, attachment upon or prior judgment, or attachment in aid of execution of judgment, or from execution of
a judgment, or other legal process or proceeding for the giving of any relief or for the enforcement of a judgment, in any such
court, with respect to its obligations, liabilities or any other matter under or arising out of or in connection with this Agreement
or any of the other Transaction Documents. To the extent that the Company or any of its respective properties, assets or revenues
may have or may hereafter become entitled to any such right of immunity in any such court in which proceedings may at any time
be commenced, the Company waives or will waive such right to the extent permitted by law and has consented to such relief and
enforcement as provided in Section 12(a) of this Agreement.


 




    	-19-



    	 



    

 


(gg)       No
Disqualification Events. None of the Company, any of its predecessors, any affiliated issuer, any director, executive officer,
other officer of the Company participating in the offering contemplated hereby, any beneficial owner of 20% or more of the Company’s
outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule
405 under the Securities Act) connected with the Company in any capacity at the time of sale (each, an “Issuer Covered
Person”) is subject to any of the “Bad Actor” disqualifications described in Rule 506(d)(1)(i) to (viii)
under the Securities Act (a “Disqualification Event”), except for a Disqualification Event covered by Rule
506(d)(2) or (d)(3) under the Securities Act. The Company has exercised reasonable care to determine whether any Issuer Covered
Person is subject to a Disqualification Event.


 


5.        COVENANTS.


 


(a)       Filing
of Form 6-K Report and Registration Statement. The Company agrees that it shall, within two (2) Business Days after the date
of this Agreement, file with the SEC a report on Form 6-K relating to the transactions contemplated by, and describing the material
terms and conditions of, the Transaction Documents (the “Form 6-K Report”). The Company shall also file with
the SEC, within ten (10) Business Days from the date hereof, a new registration statement (the “Registration Statement”)
covering only the resale of the Purchase Shares (including, without limitation, all of the Initial Purchase Shares) and all of
the Commitment Shares, in accordance with the terms of the Registration Rights Agreement between the Company and the Investor,
dated as of the date hereof (the “Registration Rights Agreement”). The Company shall permit the Investor to
review and comment upon a substantially complete pre-filing draft of the Form 6-K Report and the Registration Statement at least
two (2) Business Days prior to their filing with the SEC, and the Company shall give reasonable consideration to all such comments.
The Investor shall use its reasonable best efforts to comment upon the Form 6-K Report and the Registration Statement within one
(1) Business Day from the date the Investor receives such substantially complete pre-filing draft versions thereof from the Company.


 


(b)       Blue
Sky. The Company shall take all such action, if any, as is reasonably necessary in order to obtain an exemption for or to
register or qualify (i) the issuance of the Commitment Shares and the sale of the Purchase Shares to the Investor under this Agreement
and (ii) any subsequent resale of all Commitment Shares and all Purchase Shares by the Investor, in each case, under applicable
securities or “Blue Sky” laws of the states of the United States in such states as is reasonably requested by the
Investor from time to time, and shall provide evidence of any such action so taken to the Investor.


 


(c)       Listing/DTC.
The Company shall promptly secure the listing of all of the Purchase Shares and Commitment Shares to be issued to the Investor
hereunder on the Principal Market (subject to official notice of issuance) and upon each other national securities exchange or
automated quotation system, if any, upon which the Ordinary Shares are then listed, and shall maintain, so long as any Ordinary
Shares shall be so listed, such listing of all such Securities from time to time issuable hereunder. The Company shall maintain
the listing of the Ordinary Shares on the Principal Market and shall comply in all respects with the Company’s reporting,
filing and other obligations under the bylaws or rules and regulations of the Principal Market. Neither the Company nor any of
its Subsidiaries shall take any action that would reasonably be expected to result in the delisting or suspension of the Ordinary
Shares on the Principal Market. The Company shall promptly, and in no event later than the following Business Day, provide to
the Investor copies of any notices it receives from any Person regarding the continued eligibility of the Ordinary Shares for
listing on the Principal Market. The Company shall pay all fees and expenses in connection with satisfying its obligations under
this Section 5(c). The Company shall take all action necessary to ensure that its Ordinary Shares can be transferred electronically
as DWAC Shares.


 




    	-20-



    	 



    

 


(d)       Prohibition
of Short Sales and Hedging Transactions. The Investor agrees that beginning on the date of this Agreement and ending on the
date of termination of this Agreement as provided in Section 11, the Investor and its agents, representatives and affiliates shall
not in any manner whatsoever enter into or effect, directly or indirectly, any (i) “short sale” (as such term is defined
in Rule 200 of Regulation SHO of the Exchange Act) of the Ordinary Shares or (ii) hedging transaction, which establishes a net
short position with respect to the Ordinary Shares.


 


(e)       Issuance
of Commitment Shares. In consideration for the Investor’s execution and delivery of this Agreement, the Company shall
cause to be issued to the Investor a total of Five Million Eight Hundred Twelve Thousand Five Hundred (5,812,500) Ordinary Shares
(the “Commitment Shares”) on the date of this Agreement and shall, concurrently with the execution of this
Agreement on the date hereof, deliver to the Transfer Agent the Irrevocable Transfer Agent Instructions with respect to the issuance
of such Commitment Shares to the Investor on the date of this Agreement. For the avoidance of doubt, all of the Commitment Shares
shall be fully earned as of the date of this Agreement, whether or not the Commencement shall occur or any Purchase Shares (other
than the Initial Purchase Shares) are purchased by the Investor under this Agreement and irrespective of any subsequent termination
of this Agreement.


 


(f)        Due
Diligence; Non-Public Information. The Investor shall have the right, from time to time as the Investor may reasonably deem
appropriate, to perform reasonable due diligence on the Company during normal business hours. The Company and its officers and
employees shall provide information and reasonably cooperate with the Investor in connection with any reasonable request by the
Investor related to the Investor’s due diligence of the Company. Each party hereto agrees not to disclose any Confidential Information
of the other party to any third party and shall not use the Confidential Information for any purpose other than in connection
with, or in furtherance of, the transactions contemplated hereby. Each party hereto acknowledges that the Confidential Information
shall remain the property of the disclosing party and agrees that it shall take all reasonable measures to protect the secrecy
of any Confidential Information disclosed by the other party. The Company confirms that neither it nor any other Person acting
on its behalf shall provide the Investor or its agents or counsel with any information that constitutes or may constitute or be
deemed to constitute material, non-public information, unless a simultaneous public announcement thereof is made by the Company
in a manner such that upon such public announcement, such information shall not constitute or be deemed to constitute material,
non-public information. In the event of a breach of the foregoing covenant by the Company or any Person acting on its behalf (as
determined in the reasonable good faith judgment of the Investor), in addition to any other remedy provided herein or in the other
Transaction Documents, if the Investor or any of its affiliates owns or holds, directly or indirectly, any Securities at the time
of the disclosure of material, non-public information, the Investor shall have the right to make a public disclosure, in the form
of a press release, public advertisement or otherwise, of such material, non-public information without the prior approval by
the Company; provided the Investor shall have first provided notice to the Company that it believes it has received information
that constitutes material, non-public information, the Company shall have at least 24 hours to publicly disclose such material,
non-public information prior to any such disclosure by the Investor, and the Company shall have failed to publicly disclose such
material, non-public information within such time period. Neither the Investor, nor any of its affiliates, shareholders, members,
officers, directors, employees and direct or indirect investors, nor and any of the foregoing Person’s agents or other representatives
(including, without limitation, those retained in connection with the transactions contemplated by the Transaction Documents),
shall have any liability to the Company, any of its Subsidiaries, or any of their respective directors, officers, employees, shareholders
or agents, for any such public disclosure. The Company understands and confirms that the Investor shall be relying on the foregoing
covenants in effecting transactions in securities of the Company.


 




    	-21-



    	 



    

 


(g)       Purchase Records. The Investor and the Company shall each maintain records showing
the remaining Available Amount at any given time and the dates and Purchase Amounts for each Regular Purchase, Accelerated Purchase
and Additional Accelerated Purchase and the Initial Purchase or shall use such other method, reasonably satisfactory to the Investor
and the Company.


 


(h)       Taxes. The Company shall pay any and all transfer, stamp or similar taxes that
may be payable with respect to the issuance and delivery of any Ordinary Shares to the Investor made under this Agreement.


 


(i)        Use
of Proceeds. The Company will use the net proceeds from the offering as described in the Registration Statement or the SEC
Documents.


 


(j)        Other
Transactions. During the term of this Agreement, the Company shall not enter into, announce or recommend to its shareholders
any agreement, plan, arrangement or transaction in or of which the terms thereof would restrict, materially delay, conflict with
or impair the ability or right of the Company to perform its obligations under the Transaction Documents, including, without limitation,
the obligation of the Company to deliver the Purchase Shares and the Commitment Shares to the Investor in accordance with the
terms of the Transaction Documents.


 


(k)       Integration.
From and after the date of this Agreement, neither the Company, nor or any of its affiliates will, and the Company shall use its
reasonable best efforts to ensure that no Person acting on their behalf will, directly or indirectly, make any offers or sales
of any security or solicit any offers to buy any security, under circumstances that would cause this offering of the Securities
by the Company to the Investor to be “integrated” (within the meaning of the Securities Act) with any other offering
by the Company in a manner that would require registration of the offer and sale by the Company to the Investor of any of the
Securities under the Securities Act.


 


(l)        Limitation
on Variable Rate Transactions. From and after the date of this Agreement until the later of (i) the 24-month anniversary of
the date of this Agreement and (ii) the 24-month anniversary of the Commencement Date (if the Commencement has occurred), in either
case irrespective of any earlier termination of this Agreement, the Company shall be prohibited from effecting or entering into
an agreement to effect any issuance by the Company or any of its Subsidiaries of Ordinary Shares or Ordinary Shares Equivalents
(or a combination of units thereof) involving a Variable Rate Transaction, other than in connection with an Exempt Issuance. The
Investor shall be entitled to obtain injunctive relief against the Company and its Subsidiaries to preclude any such issuance,
which remedy shall be in addition to any right to collect damages, without the necessity of showing economic loss and without
any bond or other security being required. “Ordinary Shares Equivalents” means any securities of the Company
or its Subsidiaries which entitle the holder thereof to acquire at any time Ordinary Shares, including, without limitation, any
debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exercisable or exchangeable
for, or otherwise entitles the holder thereof to receive, Ordinary Shares. “Variable Rate Transaction” means
a transaction in which the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or
exercisable for, or include the right to receive additional Ordinary Shares or Ordinary Shares Equivalents either (A) at a conversion
price, exercise price, exchange rate or other price that is based upon and/or varies with the trading prices of or quotations
for the Ordinary Shares at any time after the initial issuance of such debt or equity securities (including, without limitation,
pursuant to any “cashless exercise” provision), or (B) with a conversion, exercise or exchange price that is subject
to being reset at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified
or contingent events directly or indirectly related to the business of the Company or the market for the Ordinary Shares (including,
without limitation, any “full ratchet” or “weighted average” anti-dilution provisions), (ii) issues or
sells any debt or equity securities, including without limitation, Ordinary Shares or Ordinary Shares Equivalents, either (A)
at a price that is subject to being reset at some future date after the initial issuance of such debt or equity security or upon
the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for
the Ordinary Shares, or (B) that is subject to or contains any put, call, redemption, buy-back, price-reset or other similar provision
or mechanism (including, without limitation, a “Black-Scholes” put or call right) that provides for the issuance of
additional debt or equity securities of the Company or the payment of cash by the Company, or (iii) enters into any agreement,
including, but not limited to, an “equity line of credit”, “at-the-market offering” or other continuous
offering or similar offering of Ordinary Shares or Ordinary Shares Equivalents, whereby the Company may sell Ordinary Shares or
Ordinary Shares Equivalents at a future determined price. “Exempt Issuance” means the issuance of (a) Ordinary
Shares or options to employees, officers, directors or vendors of the Company pursuant to any stock or option plan duly adopted
for such purpose, by the Board of Directors or a majority of the members of a committee of directors established for such purpose,
(b) any Securities issued to the Investor pursuant to this Agreement or any other agreement between the Company and the Investor,
(c) any securities issued upon the exercise or exchange of or conversion of any Securities, Ordinary Shares or Ordinary Shares
Equivalents owned or held, directly or indirectly, by the Investor at any time, (d) any securities, including, without limitation,
Ordinary Shares or Ordinary Shares Equivalents (or any combination of units thereof), issuable to the Investor or any of its affiliates
or designees pursuant to any other agreement or arrangement between the Investor or any of its affiliates or designees, on the
one hand, and the Company or any of its Subsidiaries, on the other hand, entered into after the date of this Agreement, if any,
(e) securities upon the exercise or exchange of or conversion of any Ordinary Shares Equivalents issued and outstanding on the
date of this Agreement, provided that such securities have not been amended since the date of this Agreement to increase the number
of such securities or to decrease the exercise price, exchange price or conversion price of such securities, (f) securities issued
pursuant to acquisitions or strategic transactions approved by the Board of Directors or a majority of the members of a committee
of directors established for such purpose, which acquisitions or strategic transactions can have a Variable Rate Transaction component,
provided that any such issuance shall only be to a Person (or to the equity holders of a Person) which is, itself or through its
subsidiaries, an operating company or an asset in a business synergistic with the business of the Company and shall provide to
the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company
is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities,
or (g) Ordinary Shares issued pursuant to an “at-the-market offering” by the Company exclusively through one or more
registered broker-dealers acting primarily as agent(s) of the Company pursuant to a written equity distribution or sales agreement
between the Company and such registered broker-dealer(s).


 




    	-22-



    	 



    

 


6.        TRANSFER
AGENT INSTRUCTIONS.


 


(b)       On the date of this Agreement, the Company shall issue irrevocable instructions to the Transfer Agent substantially in the form
attached hereto as Exhibit C to issue the Initial Purchase Shares and the Commitment Shares in accordance with the
terms of this Agreement (the “Irrevocable Transfer Agent Instructions”). The certificate(s) or book-entry statement(s)
representing the Initial Purchase Shares and the Commitment Shares, except as set forth below, shall bear the following restrictive
legend (the “Restrictive Legend”):


 


THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE
STATE SECURITIES LAWS. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR
ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED,
OR APPLICABLE STATE SECURITIES LAWS, UNLESS SOLD PURSUANT TO: (1) RULE 144 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (2)
AN OPINION OF HOLDER’S COUNSEL, IN A CUSTOMARY FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR APPLICABLE STATE
SECURITIES LAWS.


 


(c)       On
the earlier of (i) the Commencement Date and (ii) such time that the Investor shall request, provided all conditions of Rule 144
under the Securities Act are met, the Company shall, no later than two (2) Business Days following the delivery by the Investor
to the Company or the Transfer Agent of one or more legended certificates or book-entry statements representing the Initial Purchase
Shares and/or Commitment Shares (which certificates or book-entry statements the Investor shall promptly deliver on or prior to
the first to occur of the events described in clauses (i) and (ii) of this sentence), as directed by the Investor, issue and deliver
(or cause to be issued and delivered) to the Investor, as requested by the Investor, either: (A) a certificate or book-entry statement
representing such Initial Purchase Shares and/or Commitment Shares that is free from all restrictive and other legends or (B)
a number of Ordinary Shares equal to the number of Initial Purchase Shares and/or Commitment Shares represented by the certificate(s)
or book-entry statement(s) so delivered by the Investor as DWAC Shares. The Company shall take all actions necessary or desirable
to carry out the intent and accomplish the purposes of the immediately preceding sentence, including, without limitation, delivering
all such legal opinions, consents, certificates, resolutions and instructions to the Transfer Agent, and any successor transfer
agent of the Company, as may be requested from time to time by the Investor or necessary or desirable to carry out the intent
and accomplish the purposes of the immediately preceding sentence. On the Commencement Date, the Company shall issue to the Transfer
Agent, and any subsequent transfer agent, (i) irrevocable instructions in the form substantially similar to those used by the
Investor in substantially similar transactions (the “Commencement Irrevocable Transfer Agent Instructions”)
and (ii) the notice of effectiveness of the Registration Statement in the form attached as an exhibit to the Registration Rights
Agreement (the “Notice of Effectiveness of Registration Statement”), in each case to issue the Commitment Shares
and the Purchase Shares in accordance with the terms of this Agreement and the Registration Rights Agreement. All Purchase Shares
to be issued from and after Commencement to or for the benefit of the Investor pursuant to this Agreement shall be issued only
as DWAC Shares. The Company represents and warrants to the Investor that, while this Agreement is effective, no instruction other
than the Commencement Irrevocable Transfer Agent Instructions and the Notice of Effectiveness of Registration Statement referred
to in this Section 6(b) will be given by the Company to the Transfer Agent with respect to the Purchase Shares or the Commitment
Shares from and after Commencement, and the Purchase Shares and the Commitment Shares covered by the Registration Statement shall
otherwise be freely transferable on the books and records of the Company. The Company agrees that if the Company fails to fully
comply with the provisions of this Section 6(b) within five (5) Business Days of the Investor providing the deliveries
referred to above, the Company shall, at the Investor’s written instruction, purchase such Ordinary Shares containing the
Restrictive Legend from the Investor at the greater of the (i) purchase price paid for such Ordinary Shares (as applicable) and
(ii) the Closing Sale Price of an Ordinary Share on the date of the Investor’s written instruction.


 




    	-23-



    	 



    

 


7.        CONDITIONS
TO THE COMPANY’S RIGHT TO COMMENCE SALES OF ORDINARY SHARES.


 


I.         The
right of the Company hereunder to sell the Initial Purchase Shares on the date of this Agreement is subject to the satisfaction
of each of the following conditions:


 


(a)       The Investor shall have executed each of the Transaction Documents and delivered the
same to the Company; and


 


(b)       The representations and warranties of the Investor shall be true and correct in all
material respects as of the date hereof.


 


II.        The right of the Company hereunder to commence sales of the Purchase Shares (other than
the Initial Purchase Shares) on the Commencement Date is subject to the satisfaction of each of the following conditions:


 


(a)       The Investor shall have executed each of the Transaction Documents and delivered the
same to the Company;


 


(b)       The Registration Statement covering the resale of the Purchase Shares (including, without
limitation, all of the Initial Purchase Shares) and all of the Commitment Shares shall have been declared effective under the
Securities Act by the SEC, and no stop order with respect to the Registration Statement shall be pending or threatened by the
SEC; and


 


(c)       The representations and warranties of the Investor shall be true and correct in all
material respects as of the date hereof and as of the Commencement Date as though made at that time.


 


8.        CONDITIONS
TO THE INVESTOR’S OBLIGATION TO PURCHASE ORDINARY SHARES.




 


I.         The
obligation of the Investor to buy the Initial Purchase Shares under this Agreement is subject to the satisfaction of each of the
following conditions:


 


(a)       The
Company shall have executed each of the Transaction Documents and delivered the same to the Investor;


 


(b)       The
Ordinary Shares shall be listed or quoted on the Principal Market, trading in the Ordinary Shares shall not have been within the
last 365 days suspended by the SEC or the Principal Market, and all Securities to be issued by the Company to the Investor pursuant
to this Agreement shall have been, if applicable, approved for listing or quotation on the Principal Market in accordance with
the applicable rules and regulations of the Principal Market, subject only to official notice of issuance;


 




    	-24-



    	 



    

 


(c)       The
representations and warranties of the Company contained in Section 4 shall be true and correct in all material respects
(except to the extent that any of such representations and warranties is already qualified as to materiality in Section 4
above, in which case, such representations and warranties shall be true and correct without further qualification) as of the date
hereof (except for representations and warranties that speak as of a specific date, which shall be true and correct in all material
respects as of such specific date, or to the extent already qualified as to materiality in Section 4 above shall be true
and correct in all respects as of such specific date) and the Company shall have performed, satisfied and complied with the covenants,
agreements and conditions required by the Transaction Documents to be performed, satisfied or complied with by the Company at
or prior to the date hereof. The Investor shall have received a certificate, executed by the Chief Executive Officer (“CEO”),
President or Chief Financial Officer (“CFO”) of the Company, dated as of the date hereof, to the foregoing
effect in the form attached hereto as Exhibit A;


 


(d)       The
Board of Directors of the Company shall have adopted the Signing Resolutions, which shall be in full force and effect without
any amendment or supplement thereto as of the date hereof;


 


(e)       The
Irrevocable Transfer Agent Instructions shall have been delivered by the Company to the Transfer Agent (or any successor transfer
agent) and acknowledged in writing (including by email) by the Transfer Agent (or any successor transfer agent);


 


(f)       All
Israeli, U.S. federal, state, local and other foreign governmental laws, rules and regulations applicable to the transactions
contemplated by the Transaction Documents and necessary for the execution, delivery and performance of the Transaction Documents
and the consummation of the transactions contemplated thereby in accordance with the terms thereof shall have been complied with,
and all consents, authorizations and orders of, and all filings and registrations with, all federal, state, local and foreign
courts or governmental agencies and all federal, state, local and foreign regulatory or self-regulatory agencies necessary for
the execution, delivery and performance of the Transaction Documents and the consummation of the transactions contemplated thereby
in accordance with the terms thereof shall have been obtained or made, including, without limitation, in each case those required
under the Securities Act, the Exchange Act, the Securities Law, the Companies Law, applicable state securities or “Blue
Sky” laws or foreign laws or applicable rules and regulations of the Principal Market or otherwise required by the SEC,
the ISA, the Principal Market, or any foreign or state securities regulators;


 


(g)       No
statute, regulation, order, decree, writ, ruling or injunction shall have been enacted, entered, promulgated, threatened or endorsed
by any federal, state, local, Israeli or foreign court or governmental authority of competent jurisdiction which prohibits the
consummation of or which would materially modify or delay any of the transactions contemplated by the Transaction Documents; and


 


(h)       No
action, suit or proceeding before any federal, state, local or foreign arbitrator or any court or governmental authority of competent
jurisdiction shall have been commenced or threatened, and no inquiry or investigation by any federal, state, local or foreign
governmental authority of competent jurisdiction shall have been commenced or threatened, against the Company, or any of the officers,
directors or affiliates of the Company, seeking to restrain, prevent or change the transactions contemplated by the Transaction
Documents, or seeking material damages in connection with such transactions.


 






    	-25-



    	 



    


 


II.        The obligation of the Investor to buy Purchase Shares (other than the Initial Purchase
Shares) under this Agreement is subject to the satisfaction of each of the following conditions on or prior to the Commencement
Date and, once such conditions have been initially satisfied, there shall not be any ongoing obligation to satisfy such conditions
after the Commencement has occurred:


 


(a)       The
Company shall have executed each of the Transaction Documents and delivered the same to the Investor;


 


(b)       The
Company shall have issued or caused to be issued to the Investor (i) one or more certificates or book-entry statements representing
the Initial Purchase Shares and the Commitment Shares free from all restrictive and other legends or (ii) a number of Ordinary
Shares equal to the number of Initial Purchase Shares and Commitment Shares as DWAC Shares, in each case in accordance with Section
6(b);


 


(c)       The
Ordinary Shares shall be listed or quoted on the Principal Market, trading in the Ordinary Shares shall not have been within the
last 365 days suspended by the SEC or the Principal Market, and all Securities to be issued by the Company to the Investor pursuant
to this Agreement shall have been, if applicable, approved for listing or quotation on the Principal Market in accordance with
the applicable rules and regulations of the Principal Market, subject only to official notice of issuance;


 


(d)       The
Investor shall have received the opinions and negative assurance of the Company’s U.S. legal counsel and the opinions of the Company’s
Israeli legal counsel, each dated as of the Commencement Date substantially in the form heretofore agreed by the parties hereto;


 


(e)       The
representations and warranties of the Company contained in Section 4 shall be true and correct in all material respects
(except to the extent that any of such representations and warranties is already qualified as to materiality in Section 4
above, in which case, such representations and warranties shall be true and correct without further qualification) as of the date
hereof and as of the Commencement Date as though made at that time (except for representations and warranties that speak as of
a specific date, which shall be true and correct in all material respects as of such specific date, or to the extent already qualified
as to materiality in Section 4 above shall be true and correct in all respects as of such specific date) and the Company
shall have performed, satisfied and complied with the covenants, agreements and conditions required by the Transaction Documents
to be performed, satisfied or complied with by the Company at or prior to the Commencement Date. The Investor shall have received
a certificate, executed by the CEO, President or CFO of the Company, dated as of the Commencement Date, to the foregoing effect
in the form attached hereto as Exhibit A;


 


(f)        The
Board of Directors of the Company shall have adopted the Signing Resolutions, which shall be in full force and effect without
any amendment or supplement thereto as of the Commencement Date;


 


(g)       As
of the Commencement Date, the Company shall have reserved out of its authorized and unissued Ordinary Shares, solely for the purpose
of effecting purchases of Purchase Shares (other than the Initial Purchase Shares) hereunder, 200,000,000 Ordinary Shares;


 


(h)       The
Commencement Irrevocable Transfer Agent Instructions and the Notice of Effectiveness of Registration Statement each shall have
been delivered to the Transfer Agent (or any successor transfer agent) and acknowledged in writing (including by email) by the
Transfer Agent (or any successor transfer agent);


 


(i)        The
Company shall have delivered to the Investor a certificate evidencing the incorporation of the Company in the State of Israel
issued by the Israeli Registrar of Companies as of a date within ten (10) Business Days of the Commencement Date;


 




    	-26-



    	 



    

 


(j)        The
Company shall have delivered to the Investor a certified copy of the Articles of Association in effect as certified by the Israeli
Registrar of Companies within ten (10) Business Days of the Commencement Date;


 


(k)       The
Company shall have delivered to the Investor a secretary’s certificate executed by the Secretary of the Company, dated as of the
Commencement Date, in the form attached hereto as Exhibit B;


 


(l)        The
Registration Statement covering the resale of the Purchase Shares (including, without limitation, all of the Initial Purchase
Shares) and all of the Commitment Shares shall have been declared effective under the Securities Act by the SEC, and no stop order
with respect to the Registration Statement shall be in effect or threatened by the SEC. The Company shall have prepared and filed
with the SEC, not later than one (1) Business Day after the effective date of the Registration Statement, a final and complete
prospectus (the preliminary form of which shall be included in the Registration Statement) and shall have delivered to the Investor
a true and complete copy thereof. Such prospectus shall be current and available for the resale by the Investor of all of the
Securities covered thereby. The Form 6-K Report shall have been filed with the SEC, as required pursuant to Section 5(a).
All reports, schedules, registrations, forms, statements, information and other documents required to have been filed by the Company
with the SEC and the ISA at or prior to the Commencement Date pursuant to the reporting requirements of the Securities Act, the
Exchange Act and the Securities Law shall have been filed with the SEC and ISA within the applicable time periods prescribed for
such filings under the Securities Act, the Exchange Act and the Securities Law, as applicable;


 


(m)       No
Event of Default (as defined below) has occurred, and no event which, after notice and/or lapse of time, would reasonably be expected
to become an Event of Default has occurred;


 


(n)       All
Israeli, U.S. federal, state, local and other foreign governmental laws, rules and regulations applicable to the transactions
contemplated by the Transaction Documents and necessary for the execution, delivery and performance of the Transaction Documents
and the consummation of the transactions contemplated thereby in accordance with the terms thereof shall have been complied with,
and all consents, authorizations and orders of, and all filings and registrations with, all Israeli and federal, state and local
courts or governmental agencies and all federal, state and local regulatory or self-regulatory agencies necessary for the execution,
delivery and performance of the Transaction Documents and the consummation of the transactions contemplated thereby in accordance
with the terms thereof shall have been obtained or made, including, without limitation, in each case those required under the
Securities Act, the Exchange Act, the Securities Law, the Companies Law, applicable state securities or “Blue Sky”
laws or foreign laws or applicable rules and regulations of the Principal Market, or otherwise required by the SEC, the ISA, the
Principal Market or any foreign or state securities regulators;


 


(o)       No
statute, regulation, order, decree, writ, ruling or injunction shall have been enacted, entered, promulgated, threatened or endorsed
by any Israeli or U.S. federal, state, local or foreign court or governmental authority of competent jurisdiction which prohibits
the consummation of or which would materially modify or delay any of the transactions contemplated by the Transaction Documents;
and


 


(p)       No
action, suit or proceeding before any Israeli or U.S. federal, state, local or foreign arbitrator or any court or governmental
authority of competent jurisdiction shall have been commenced or threatened, and no inquiry or investigation by any federal, state,
local or foreign governmental authority of competent jurisdiction shall have been commenced or threatened, against the Company,
or any of the officers, directors or affiliates of the Company, seeking to restrain, prevent or change the transactions contemplated
by the Transaction Documents, or seeking material damages in connection with such transactions.


 




    	-27-



    	 



    

 


9.         INDEMNIFICATION.





 


In
consideration of the Investor’s execution and delivery of the Transaction Documents and acquiring the Securities hereunder and
in addition to all of the Company’s other obligations under the Transaction Documents, the Company shall defend, protect, indemnify
and hold harmless the Investor and all of its affiliates, stockholders, members, officers, directors, employees and direct or
indirect investors and any of the foregoing Person’s agents or other representatives (including, without limitation, those retained
in connection with the transactions contemplated by this Agreement) (collectively, the “Indemnitees”) from and
against any and all actions, causes of action, suits, claims, losses, costs, penalties, fees, liabilities and damages, and expenses
in connection therewith (irrespective of whether any such Indemnitee is a party to the action for which indemnification hereunder
is sought), and including reasonable attorneys’ fees and disbursements (the “Indemnified Liabilities”), incurred
by any Indemnitee as a result of, or arising out of, or relating to (a) any misrepresentation or breach of any representation
or warranty made by the Company in the Transaction Documents or any other certificate, instrument or document contemplated hereby
or thereby, (b) any breach of any covenant, agreement or obligation of the Company contained in the Transaction Documents or any
other certificate, instrument or document contemplated hereby or thereby, or (c) any cause of action, suit or claim brought or
made against such Indemnitee and arising out of or resulting from the execution, delivery, performance or enforcement of the Transaction
Documents or any other certificate, instrument or document contemplated hereby or thereby, other than, in the case of clause (c),
with respect to Indemnified Liabilities which directly and primarily result from the fraud, gross negligence or willful misconduct
of an Indemnitee. The indemnity in this Section 9 shall not apply to amounts paid in settlement of any claim if such settlement
is effected without the prior written consent of the Company, which consent shall not be unreasonably withheld, conditioned or
delayed. To the extent that the foregoing undertaking by the Company may be unenforceable for any reason, the Company shall make
the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities which is permissible under applicable
law. Payment under this indemnification shall be made within thirty (30) days from the date Investor makes written request for
it. A certificate containing reasonable detail as to the amount of such indemnification submitted to the Company by Investor shall
be conclusive evidence, absent manifest error, of the amount due from the Company to Investor. If any action shall be brought
against any Indemnitee in respect of which indemnity may be sought pursuant to this Agreement, such Indemnitee shall promptly
notify the Company in writing, and the Company shall have the right to assume the defense thereof with counsel of its own choosing
reasonably acceptable to the Indemnitee. Any Indemnitee shall have the right to employ separate counsel in any such action and
participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Indemnitee, except
to the extent that (i) the employment thereof has been specifically authorized by the Company in writing, (ii) the Company has
failed after a reasonable period of time to assume such defense and to employ counsel or (iii) in such action there is, in the
reasonable opinion of such separate counsel, a material conflict on any material issue between the position of the Company and
the position of such Indemnitee, in which case the Company shall be responsible for the reasonable fees and expenses of no more
than one such separate counsel.


 




    	-28-



    	 



    

 


10.      EVENTS
OF DEFAULT. 


 


An
“Event of Default” shall be deemed to have occurred at any time as any of the following events occurs:


 


(a)       the
effectiveness of a registration statement registering the resale of the Securities lapses for any reason (including, without limitation,
the issuance of a stop order or similar order) or such registration statement (or the prospectus forming a part thereof) is unavailable
to the Investor for resale of any or all of the Securities to be issued to the Investor under the Transaction Documents, and such
lapse or unavailability continues for a period of ten (10) consecutive Business Days or for more than an aggregate of thirty (30)
Business Days in any 365-day period, but excluding a lapse or unavailability where (i) the Company terminates a registration statement
after the Investor has confirmed in writing that all of the Securities covered thereby have been resold or (ii) the Company supersedes
one registration statement with another registration statement, including (without limitation) by terminating a prior registration
statement when it is effectively replaced with a new registration statement covering Securities (provided in the case of this
clause (ii) that all of the Securities covered by the superseded (or terminated) registration statement that have not theretofore
been resold are included in the superseding (or new) registration statement);


 


(b)       the
suspension of the Ordinary Shares from trading on the Principal Market for a period of one (1) Business Day, provided that the
Company may not direct the Investor to purchase any Ordinary Shares during any such suspension;


 


(c)       the
delisting of the Ordinary Shares from OTC Markets (or nationally recognized successor to the foregoing), provided, however, that
the Ordinary Shares are not immediately thereafter trading on the New York Stock Exchange, The Nasdaq Capital Market, The Nasdaq
Global Market, The Nasdaq Global Select Market, the NYSE American, the NYSE Arca, or the OTC Bulletin Board (or nationally recognized
successor to any of the foregoing);


 


(d)       the
failure for any reason by the Transfer Agent to issue Purchase Shares to the Investor within two (2) Business Days after the date
on which the Investor is entitled to receive such Purchase Shares under this Agreement;


 


(e)       the
Company breaches any representation, warranty, covenant or other term or condition under any Transaction Document if such breach
would reasonably be expected to have a Material Adverse Effect and except, in the case of a breach of a covenant which is reasonably
curable, only if such breach continues for a period of at least five (5) Business Days;


 


(f)       if
any Person commences a proceeding against the Company pursuant to or within the meaning of any Bankruptcy Law;


 


(g)       except
with respect to proceedings under s.350 of the Israeli Companies Law 1999 relating only to technical arrangements with the Company’s
security holders not related to matters of insolvency and which do not derogate from the rights or remedies of the Investor hereunder,
if the Company pursuant to or within the meaning of any Bankruptcy Law; (i) commences a voluntary case, (ii) consents to the entry
of an order for relief against it in an involuntary case, (iii) consents to the appointment of a Custodian of it or for all or
substantially all of its property, or (iv) makes a general assignment for the benefit of its creditors or is generally unable
to pay its debts as the same become due;


 


(h)       a
court of competent jurisdiction enters an order or decree under any Bankruptcy Law that (i) is for relief against the Company
in an involuntary case, (ii) appoints a Custodian of the Company or for all or substantially all of its property, or (iii) orders
the liquidation of the Company or any Subsidiary; or


 




    	-29-



    	 



    

 


(i)        if
at any time the Company is not eligible to transfer its Ordinary Shares electronically as DWAC Shares.


 


In
addition to any other rights and remedies under applicable law and this Agreement, so long as an Event of Default has occurred
and is continuing, or if any event which, after notice and/or lapse of time, would reasonably be expected to become an Event of
Default, has occurred and is continuing, the Company shall not deliver to the Investor any Regular Purchase Notice, Accelerated
Purchase Notice or Additional Accelerated Purchase Notice.


 


11.       TERMINATION


 


This
Agreement may be terminated only as follows:


 


(a)       Except
with respect to proceedings under s.350 of the Israeli Companies Law 1999 relating only to technical arrangements with the Company’s
security holders not related to matters of insolvency and which do not derogate from the rights or remedies of the Investor hereunder,
if pursuant to or within the meaning of any Bankruptcy Law, the Company commences a voluntary case or any Person commences a proceeding
against the Company, which is not dismissed within thirty (30) days, a Custodian is appointed for the Company or for all or substantially
all of its property, or the Company makes a general assignment for the benefit of its creditors, (any of which would be an Event
of Default as described in Sections 10(f), 10(g) and 10(h) hereof) this Agreement shall automatically terminate
without any liability or payment to the Company (except as set forth below) without further action or notice by any Person.


 


(b)       In
the event that (i) the Company fails to file the Registration Statement with the SEC within the period specified in Section
5(a) hereof in accordance with the terms of the Registration Rights Agreement or (ii) the Commencement shall not have occurred
on or before December 31, 2020, due to the failure to satisfy the conditions set forth in Sections 7(II) and 8(II)
above with respect to the Commencement, then, in the case of clause (i) above, this Agreement may be terminated by the Investor
at any time prior to the filing of the Registration Statement and, in the case of clause (ii) above, this Agreement may be terminated
by either party at the close of business on December 31, 2020 or thereafter, in each case without liability of such party to the
other party (except as set forth below); provided, however, that the right to terminate this Agreement under this Section 11(b)
shall not be available to any party if such party is then in breach of any covenant or agreement contained in this Agreement
or any representation or warranty of such party contained in this Agreement fails to be true and correct such that the conditions
set forth in Section 7(II)(c) or Section 8(II)(e), as applicable, could not then be satisfied.


 


(c)       
At any time after the Commencement Date, the Company shall have the option to terminate this Agreement for any reason or for no
reason by delivering notice (a “Company Termination Notice”) to the Investor electing to terminate this Agreement
without any liability whatsoever of any party to any other party under this Agreement (except as set forth below). The Company
Termination Notice shall not be effective until one (1) Business Day after it has been received by the Investor.


 


(d)       This
Agreement shall automatically terminate on the date that the Company sells and the Investor purchases the full Available Amount
as provided herein, without any action or notice on the part of any party and without any liability whatsoever of any party to
any other party under this Agreement (except as set forth below).


 




    	-30-



    	 



    

 


(e)       If,
for any reason or for no reason, the full Available Amount has not been purchased in accordance with Section 2 of this
Agreement by the Maturity Date, this Agreement shall automatically terminate on the Maturity Date, without any action or notice
on the part of any party and without any liability whatsoever of any party to any other party under this Agreement (except as
set forth below).


 


Except
as set forth in Sections 11(a) (in respect of an Event of Default under Sections 10(f), 10(g) and 10(h)),
11(d) and 11(e), any termination of this Agreement pursuant to this Section 11 shall be effected by written
notice from the Company to the Investor, or the Investor to the Company, as the case may be, setting forth the basis for the termination
hereof. The representations and warranties and covenants of the Company and the Investor contained in Sections 3, 4,
5, and 6 hereof, the indemnification provisions set forth in Section 9 hereof and the agreements and covenants
set forth in Sections 10, 11 and 12 shall survive the execution and delivery of this Agreement and any termination
of this Agreement. No termination of this Agreement shall (i) affect the Company’s or the Investor’s rights or obligations
under (A) this Agreement with respect to the Initial Purchase or any pending Regular Purchases, Accelerated Purchases or Additional
Accelerated Purchases and the Company and the Investor shall complete their respective obligations with respect to the Initial
Purchase and any pending Regular Purchases, Accelerated Purchases and Additional Accelerated Purchases under this Agreement and
(B) the Registration Rights Agreement, which shall survive any such termination, or (ii) be deemed to release the Company or the
Investor from any liability for intentional misrepresentation or willful breach of any of the Transaction Documents.


 


12.       MISCELLANEOUS.


 


(a)       Governing
Law; Jurisdiction; Jury Trial. The laws of the State of Israel shall govern all issues concerning the relative rights of the
Company and its stockholders. All other questions concerning the construction, validity, enforcement and interpretation of this
Agreement, the Registration Rights Agreement and the other Transaction Documents shall be governed by the internal laws of the
State of Delaware, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Delaware
or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of Delaware.
Any legal suit, action or proceeding arising out of or based upon the Securities, this Agreement, the Registration Rights Agreement
or any of the other Transaction Documents or any of the transactions contemplated hereby or thereby (“Related Proceedings”)
may be instituted in any of the federal courts of the United States of America or any of the courts of the State of Delaware,
in each case located in the State of Delaware (collectively, the “Specified Courts”), and each party irrevocably
submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment of any such
court (a “Related Judgment”), as to which such jurisdiction is non-exclusive) of any of the Specified Courts
in any such suit, action or proceeding. Service of any process, summons, notice or document by mail to such party’s address
set forth above shall be effective service of process for any suit, action or other proceeding brought in any of the Specified
Courts. The parties irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding
in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any of the Specified Courts
that any such suit, action or other proceeding brought in any of the Specified Courts has been brought in an inconvenient forum.
EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF
ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY. The
Company has irrevocably appointed Puglisi & Associates, which currently maintains an office at 850 Library Avenue, Suite 204,
Newark, Delaware 19711, as its agent to receive service of process or other legal summons for purposes of any such suit, action
or proceeding that may be instituted in any of the Specified Courts.


 




    	-31-



    	 



    

 


With
respect to any Related Proceeding, each party irrevocably waives, to the fullest extent permitted by applicable law, all immunity
(whether on the basis of sovereignty or otherwise) from jurisdiction, service of process, attachment (both before and after judgment)
and execution to which it might otherwise be entitled in the Specified Courts, and with respect to any Related Judgment, each
party waives any such immunity in the Specified Courts or any other court of competent jurisdiction, and will not raise or claim
or cause to be pleaded any such immunity at or in respect of any such Related Proceeding or Related Judgment, including, without
limitation, any immunity pursuant to the United States Foreign Sovereign Immunities Act of 1976, as amended.


 


The
obligations of the Company pursuant to this Agreement in respect of any sum due to the Investor shall, notwithstanding any judgment
in a currency other than United States dollars, not be discharged until the first business day, following receipt by the Investor
of any sum adjudged to be so due in such other currency, on which the Investor may in accordance with normal banking procedures
purchase United States dollars with such other currency. If the United States dollars so purchased are less than the sum originally
due to the Investor in United States dollars hereunder, the Company agrees as a separate obligation and notwithstanding any such
judgment, to indemnify the Investor against such loss. If the United States dollars so purchased are greater than the sum originally
due to the Investor hereunder, the Investor agrees to pay to the Company an amount equal to the excess of the dollars so purchased
over the sum originally due to the Investor hereunder. Unless otherwise expressly indicated, all dollar amounts referred to in
this Agreement and the other Transaction Documents are in United States Dollars (“U.S. Dollars”), and all amounts
owing under this Agreement and all other Transaction Documents shall be paid in U.S. Dollars. All amounts denominated in other
currencies (if any) shall be converted into the U.S. Dollar equivalent amount in accordance with the Exchange Rate (as defined
below) on the date of calculation. The term “Exchange Rate” means, in relation to any amount of currency to
be converted into U.S. Dollars pursuant to this Agreement, the U.S. Dollar exchange rate as published in the Wall Street Journal
on the relevant date of calculation.


 


All
payments made by the Company under this Agreement, if any, will be made without withholding or deduction for or on account of
any present or future taxes, duties, assessments or governmental charges of whatever nature (other than taxes on net income) imposed
or levied by or on behalf of the State of Israel, any other jurisdiction from or through which payment is made, or, in each case,
any political subdivision or any taxing authority thereof or therein unless the Company is or becomes required by law to withhold
or deduct such taxes, duties, assessments or other governmental charges. In such event, the Company will pay such additional amounts
as will result, after such withholding or deduction, in the receipt by the Investor and each person controlling the Investor,
as the case may be, of the amounts that would otherwise have been receivable in respect thereof.


 


(b)       Counterparts.
This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a
facsimile signature or signature delivered by e-mail in a “.pdf” format data file, including any electronic signature
complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com, www.echosign.adobe.com, etc., shall be considered due
execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original
signature.


 


(c)       Headings.
The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this
Agreement.


 


(d)       Severability.
If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability
shall not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability
of any provision of this Agreement in any other jurisdiction.


 




    	-32-



    	 



    

 


(e)       Entire
Agreement. The Transaction Documents supersede all other prior oral or written agreements between the Investor, the Company,
their affiliates and Persons acting on their behalf with respect to the subject matter thereof, and this Agreement, the other
Transaction Documents and the instruments referenced herein contain the entire understanding of the parties with respect to the
matters covered herein and therein and, except as specifically set forth herein or therein, neither the Company nor the Investor
makes any representation, warranty, covenant or undertaking with respect to such matters. The Company acknowledges and agrees
that is has not relied on, in any manner whatsoever, any representations or statements, written or oral, other than as expressly
set forth in the Transaction Documents.


 


(f)       Notices.
Any notices, consents or other communications required or permitted to be given under the terms of this Agreement must be in writing
and will be deemed to have been delivered: (i) upon receipt when delivered personally; (ii) upon receipt when sent by facsimile
or email (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending party);
or (iii) one Business Day after deposit with a nationally recognized overnight delivery service, in each case properly addressed
to the party to receive the same. The addresses for such communications shall be:


 





	If to the Company:
	 
	Todos Medical Ltd.
	1 Hamada Street
	Rehovot, 7670301 Israel
	Telephone:	(650) 862-5391
	E-mail:	gerald@todosmedical.com
	Attention:	Gerald Commissiong
	 
	With a copy to (which shall not constitute notice or service of process):
	 
	Sheppard Mullin Richter Hampton LLP
	30 Rockefeller Plaza
	New York, NY 10112
	Telephone:	(212) 634-3067
	Facsimile:	(917) 438-6133
	Email:	jfessler@sheppardmullin.com
	Attention:	Jeffrey J. Fessler, Esq.
	 
	If to the Investor:
	 
	Lincoln Park Capital Fund, LLC
	440 North Wells, Suite 410
	Chicago, IL 60654
	Telephone:	312-822-9300
	Facsimile:	312-822-9301
	E-mail:	jscheinfeld@lpcfunds.com/jcope@lpcfunds.com
	Attention:	Josh Scheinfeld/Jonathan Cope
	 
	With a copy to (which shall not constitute notice or service of process):
	 
	Dorsey & Whitney LLP
	51 West 52nd Street
	New York, NY 10019
	Telephone:	(212) 415-9214
	Facsimile:	(212) 953-7201
	E-mail:	marsico.anthony@dorsey.com
	Attention:	Anthony J. Marsico, Esq.


 




    	-33-



    	 



    

 





	If to the Transfer Agent:
	 
	Worldwide Stock Transfer, LLC
	1 University Plaza Drive #505
	Hackensack, NJ 07601
	Telephone:	(201) 820-2008
	Facsimile:	(201) 820-2010
	Email:	ykopstick@wwstr.com
	Attention:	Yonah Kopstick


 


or
at such other address and/or facsimile number and/or email address and/or to the attention of such other Person as the recipient
party has specified by written notice given to each other party three (3) Business Days prior to the effectiveness of such change.
Written confirmation of receipt (A) given by the recipient of such notice, consent or other communication, (B) mechanically or
electronically generated by the sender’s facsimile machine or email account containing the time, date, and recipient facsimile
number or email address, as applicable, or (C) provided by a nationally recognized overnight delivery service, shall be rebuttable
evidence of personal service, receipt by facsimile or email or receipt from a nationally recognized overnight delivery service
in accordance with clause (i), (ii) or (iii) above, respectively.


 


(g)       Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors
and assigns. The Company shall not assign this Agreement or any rights or obligations hereunder without the prior written consent
of the Investor, including by merger or consolidation. The Investor may not assign its rights or obligations under this Agreement.


 


(h)       No
Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted
successors and assigns and, except as set forth in Section 9, is not for the benefit of, nor may any provision hereof be enforced
by, any other Person.


 


(i)        Publicity.
The Company shall afford the Investor and its counsel with the opportunity to review and comment upon, shall consult with the
Investor and its counsel on the form and substance of, and shall give due consideration to all such comments from the Investor
or its counsel on, any press release, SEC filing or any other public disclosure by or on behalf of the Company relating to the
Investor, its purchases hereunder or any aspect of the Transaction Documents or the transactions contemplated thereby, not less
than 24 hours prior to the issuance, filing or public disclosure thereof. The Investor must be provided with a final version of
any portion of such press release, SEC filing or other public disclosure at least 24 hours prior to any release, filing or use
by the Company thereof. The Company agrees and acknowledges that its failure to fully comply with this provision constitutes a
Material Adverse Effect.


 


(j)        Further
Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall
execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request
in order to consummate and make effective, as soon as reasonably possible, the Commencement, and to carry out the intent and accomplish
the purposes of this Agreement and the consummation of the transactions contemplated hereby.


 


(k)       No
Financial Advisor, Placement Agent, Broker or Finder. The Company represents and warrants to the Investor that it has not
engaged any financial advisor, placement agent, broker or finder in connection with the transactions contemplated hereby. The
Investor represents and warrants to the Company that it has not engaged any financial advisor, placement agent, broker or finder
in connection with the transactions contemplated hereby. The Company shall be responsible for the payment of any fees or commissions,
if any, of any financial advisor, placement agent, broker or finder relating to or arising out of the transactions contemplated
hereby. The Company shall pay, and hold the Investor harmless against, any liability, loss or expense (including, without limitation,
reasonable attorneys’ fees and out of pocket expenses) arising in connection with any such claim.


 




    	-34-



    	 



    

 


(l)        No
Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express
their mutual intent, and no rules of strict construction will be applied against any party.


 


(m)      Remedies,
Other Obligations, Breaches and Injunctive Relief. The Investor’s remedies provided in this Agreement, including, without
limitation, the Investor’s remedies provided in Section 9, shall be cumulative and in addition to all other remedies available
to the Investor under this Agreement, at law or in equity (including a decree of specific performance and/or other injunctive
relief), no remedy of the Investor contained herein shall be deemed a waiver of compliance with the provisions giving rise to
such remedy and nothing herein shall limit the Investor’s right to pursue actual damages for any failure by the Company to comply
with the terms of this Agreement. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable
harm to the Investor and that the remedy at law for any such breach may be inadequate. The Company therefore agrees that, in the
event of any such breach or threatened breach, the Investor shall be entitled, in addition to all other available remedies, to
an injunction restraining any breach, without the necessity of showing economic loss and without any bond or other security being
required.


 


(n)       Enforcement
Costs. If: (i) this Agreement is placed by the Investor in the hands of an attorney for enforcement or is enforced by the
Investor through any legal proceeding; (ii) an attorney is retained to represent the Investor in any bankruptcy, reorganization,
receivership or other proceedings affecting creditors’ rights and involving a claim under this Agreement; or (iii) an attorney
is retained to represent the Investor in any other proceedings whatsoever in connection with this Agreement, then the Company
shall pay to the Investor, as incurred by the Investor, all reasonable costs and expenses including attorneys’ fees incurred in
connection therewith, in addition to all other amounts due hereunder. If this Agreement is placed by the Company in the hands
of an attorney for enforcement or is enforced by the Company through any legal proceeding, then the Investor shall pay to the
Company, as incurred by the Company, all reasonable costs and expenses including attorneys’ fees incurred in connection therewith,
in addition to all other amounts due hereunder.


 


(o)       Amendment
and Waiver; Failure or Indulgence Not Waiver. No provision of this Agreement may be amended or waived by the parties from
and after the date that is one (1) Business Day immediately preceding the initial filing of the Registration Statement with the
SEC. Subject to the immediately preceding sentence, (i) no provision of this Agreement may be amended other than by a written
instrument signed by both parties hereto and (ii) no provision of this Agreement may be waived other than in a written instrument
signed by the party against whom enforcement of such waiver is sought. No failure or delay in the exercise of any power, right
or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or
privilege preclude other or further exercise thereof or of any other right, power or privilege.


 


*
* * * *


 




    	-35-



    	 



    

 


IN
WITNESS WHEREOF, the Investor and the Company have caused this Agreement to be duly executed as of the date first written
above.


 


	 	THE
    COMPANY:
	 	 
	 	TODOS
    MEDICAL LTD.
	 	 
	 	By:	/s/
    Gerald Commissiong
	 	Name:	Gerald
    Commissiong
	 	Title:	Chief
    Executive Officer
	 	 
	 	INVESTOR:
	 	 
	 	LINCOLN
    PARK CAPITAL FUND, LLC
	 	BY:
    LINCOLN PARK CAPITAL, LLC
	 	BY:
    ROCKLEDGE CAPITAL CORPORATION
	 	 
	 	By:	/s/
    Josh Scheinfeld
	 	Name:	Josh
    Scheinfeld
	 	Title:	President


 




    	-36-



    	 



    

 


EXHIBITS


 


	Exhibit
    A	 	Form
    of Officer’s Certificate
	Exhibit
    B	 	Form
    of Resolutions of Board of Directors of the Company
	Exhibit
    C	 	Form
    of Secretary’s Certificate
	Exhibit
    D	 	Form
    of Letter to Transfer Agent


 




    	 



    	 



    

 


EXHIBIT
A


 


FORM
OF OFFICER’S CERTIFICATE


 


This
Officer’s Certificate (“Certificate”) is being delivered pursuant to [Section 8(I)(c)] [Section
8(II)(e)] of that certain Purchase Agreement dated as of August 4, 2020, (“Purchase Agreement”), by and between
TODOS MEDICAL LTD., a State of Israel corporation (the “Company”), and LINCOLN PARK CAPITAL FUND,
LLC (the “Investor”). Terms used herein and not otherwise defined shall have the meanings ascribed to them
in the Purchase Agreement.


 


The
undersigned, Gerald Commissiong, Chief Executive Officer of the Company, hereby certifies, on behalf of the Company and not in
his individual capacity, as follows:


 


1.       I
am the Chief Executive Officer of the Company and make the statements contained in this Certificate;


 


2.       The
representations and warranties of the Company are true and correct in all material respects (except to the extent that any of
such representations and warranties is already qualified as to materiality in Section 4 of the Purchase Agreement, in which case,
such representations and warranties are true and correct without further qualification) as of the date when made and as of [the
date hereof] [the Commencement Date] as though made at that time (except for representations and warranties that speak as of a
specific date, in which case such representations and warranties are true and correct as of such date);


 


3.       The
Company has performed, satisfied and complied in all material respects with covenants, agreements and conditions required by the
Transaction Documents to be performed, satisfied or complied with by the Company at or prior to the [the date hereof] [the Commencement
Date].


 


4.
       The Company has not taken any steps, and does not currently expect to take any steps,
to seek protection pursuant to any Bankruptcy Law nor does the Company or any of its Subsidiaries have any knowledge or reason
to believe that its creditors intend to initiate involuntary bankruptcy or insolvency proceedings. The Company is financially
solvent and is generally able to pay its debts as they become due.


 


IN
WITNESS WHEREOF, I have hereunder signed my name on this ___ day of ___________.


 


	 	 
	 	Name:
    Gerald Commissiong
	 	Title:
    Chief Executive Officer


 


The
undersigned as Secretary of TODOS MEDICAL LTD., a State of Israel corporation, hereby certifies that Gerald Commissiong
is the duly elected, appointed, qualified and acting Chief Executive Officer of TODOS MEDICAL LTD. and that the signature
appearing above is his genuine signature.


 


	 	 
	 	[________________],
    Secretary


 




    	 



    	 



    




 


EXHIBIT
B


 


FORM
OF COMPANY RESOLUTIONS


FOR
SIGNING PURCHASE AGREEMENT


 


WHEREAS,
there has been presented to the Board of Directors (the “Board”) of TODOS MEDICAL LTD., a State of Israel
corporation (the “Corporation”), a draft of the Purchase Agreement (the “Purchase Agreement”)
by and between the Corporation and Lincoln Park Capital Fund, LLC (“Lincoln Park”), providing for the purchase
by Lincoln Park of up to Ten Million Two Hundred Seventy-Five Thousand Dollars ($10,275,000) of the Company’s ordinary shares,
par value NIS $0.01 per share (the “Ordinary Shares”); and


 


WHEREAS,
after careful consideration and review of the Purchase Agreement, the documents incident thereto and other factors deemed relevant
by the Board of Directors, the Board of Directors has determined that it is advisable and in the best interests of the Corporation
to engage in the transactions contemplated by the Purchase Agreement, including, but not limited to, the issuance upon execution
of the Purchase Agreement of Three Million Four Hundred Thirty-Seven Thousand Five Hundred (3,437,500) Ordinary Shares (collectively,
the “Initial Purchase Shares”) to Lincoln Park, for aggregate consideration of Two Hundred Seventy-Five Thousand
Dollars ($275,000) (the “Initial Purchase”), and Five Million Eight Hundred Twelve Thousand Five Hundred (5,812,500)
Ordinary Shares to Lincoln Park as payment of a commitment fee (the “Commitment Shares”), and from time to
time following “Commencement” under the Purchase Agreement, the issuance and sale of additional Ordinary Shares to
Lincoln Park up to the available amount under the Purchase Agreement (collectively with the Initial Purchase Shares, the “Purchase
Shares”).


 


Transaction
Documents


 


NOW,
THEREFORE, BE IT RESOLVED, that the transactions described in the Purchase Agreement are hereby approved and each of Gerald Commissiong
and [_____________] (the “Authorized Officers”) are severally authorized to execute and deliver the Purchase
Agreement on behalf of the Company, and any other agreements or documents contemplated thereby, with such amendments, changes,
additions and deletions as the Authorized Officers may deem to be appropriate and approve on behalf of, the Corporation, such
approval to be conclusively evidenced by the signature of an Authorized Officer thereon; and


 


FURTHER
RESOLVED, that the terms and provisions of a registration rights agreement (the “Registration Rights Agreement”),
by and between the Corporation and Lincoln Park, providing for the registration of the Purchase Shares, including the Initial
Purchase Shares, and the Commitment Shares issuable in respect of the Purchase Agreement on behalf of the Corporation, a draft
of which has been provided to the Board, are hereby approved and the Authorized Officers are authorized to execute and deliver
the Registration Rights Agreement on behalf of the Company, with such amendments, changes, additions and deletions as the Authorized
Officer may deem appropriate and approve on behalf of, the Corporation, such approval to be conclusively evidenced by the signature
of an Authorized Officer thereon; and


 


FURTHER
RESOLVED, that the terms and provisions of the forms of Irrevocable Transfer Agent Instructions and Notice of Effectiveness of
Registration Statement (the “Instructions”), drafts of which has been provided to the Board, are hereby approved
and the Authorized Officers are authorized to execute and deliver the Instructions on behalf of the Company as and when set forth
in the Purchase Agreement and the Registration Rights Agreement, with such amendments, changes, additions and deletions as the
Authorized Officers may deem appropriate and approve on behalf of, the Corporation, such approval to be conclusively evidenced
by the signature of an Authorized Officer thereon; and


 




    	 



    	 



    

 


Issuance
of Purchase Shares


 


FURTHER
RESOLVED, that upon execution of the Purchase Agreement and the Registration Rights Agreement by the Corporation, the Corporation
is hereby authorized to issue and sell Three Million Four Hundred Thirty-Seven Thousand Five Hundred (3,437,500) Ordinary Shares
(subject to equitable adjustment for any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction)
to Lincoln Park as Initial Purchase Shares, for aggregate consideration of Two Hundred Seventy-Five Thousand Dollars ($275,000),
in the Initial Purchase in accordance with the terms of the Purchase Agreement and that, upon issuance of such Initial Purchase
Shares in the Initial Purchase pursuant to the Purchase Agreement, such Initial Purchase Shares will be duly authorized, validly
issued, fully paid and nonassessable; and


 


FURTHER
RESOLVED, that upon execution of the Purchase Agreement and the Registration Rights Agreement by the Corporation, the Corporation
is hereby authorized to issue Five Million Eight Hundred Twelve Thousand Five Hundred (5,812,500) Ordinary Shares (subject to
equitable adjustment for any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction) to
Lincoln Park as Commitment Shares in accordance with the terms of the Purchase Agreement and that, upon issuance of the Commitment
Shares pursuant to the Purchase Agreement, the Commitment Shares will be duly authorized, validly issued, fully paid and nonassessable;
and


 


FURTHER
RESOLVED, that the Corporation shall initially reserve 1,000,000,000 Ordinary Shares (subject to equitable adjustment for any
reorganization, recapitalization, non-cash dividend, stock split or other similar transaction) for issuance as Purchase Shares
(other than the Initial Purchase Shares) under the Purchase Agreement and that, upon issuance of such Purchase Shares pursuant
to the Purchase Agreement, such Purchase Shares will be duly authorized, validly issued, fully paid and nonassessable; and


 


Registration
Statement


 


FURTHER
RESOLVED, that the Corporation is hereby authorized to file a registration statement on Form F-1, covering the resale of the Purchase
Shares, including all of the Initial Purchase Shares, all of the Commitment Shares, in accordance with the terms of the Registration
Rights Agreement; and


 


Approval
of Actions


 


FURTHER
RESOLVED, that, without limiting the foregoing, the Authorized Officers are, and each of them hereby is, authorized and directed
to proceed on behalf of the Corporation and to take all such steps as deemed necessary or appropriate, with the advice and assistance
of counsel, to cause the Corporation to consummate the agreements referred to herein and to perform its obligations under such
agreements; and


 


FURTHER
RESOLVED, that the Authorized Officers be, and each of them hereby is, authorized, empowered and directed on behalf of and in
the name of the Corporation, to take or cause to be taken all such further actions and to execute and deliver or cause to be executed
and delivered all such further agreements, amendments, documents, certificates, reports, schedules, applications, notices, letters
and undertakings and to incur and pay all such fees and expenses as in their judgment shall be necessary, proper or desirable
to carry into effect the purpose and intent of any and all of the foregoing resolutions, and that all actions heretofore taken
by any officer or director of the Corporation in connection with the transactions contemplated by the agreements described herein
are hereby approved, ratified and confirmed in all respects.


 


(Signature
Page Follows)


 




    	 



    	 



    

 


EXHIBIT
C


 


FORM
OF SECRETARY’S CERTIFICATE


 


This
Secretary’s Certificate (“Certificate”) is being delivered pursuant to Section 8(II)(k) of that certain
Purchase Agreement dated as of August 4, 2020 (“Purchase Agreement”), by and between TODOS MEDICAL LTD., a
State of Israel corporation (the “Company”) and LINCOLN PARK CAPITAL FUND, LLC (the “Investor”),
pursuant to which the Company may sell to the Investor up to Ten Million Two Hundred Seventy-Five Thousand Dollars ($10,275,000)
of the Company’s ordinary shares, par value NIS $0.01 per share (the “Ordinary Shares”). Terms used herein and not otherwise
defined shall have the meanings ascribed to them in the Purchase Agreement.


 


The
undersigned, [_______________], Secretary of the Company, hereby certifies, on behalf of the Company and not in his individual
capacity, as follows:


 


1.       I
am the Secretary of the Company and make the statements contained in this Secretary’s Certificate.


 


2.       Attached
hereto as Exhibit A is a true, correct and complete copy of the Company’s Amended and Restated Articles of Association,
as amended through the date hereof (the “Charter”), and no action has been taken by the Company, its directors, officers
or stockholders, in contemplation of the filing of any further amendment relating to or affecting the Charter.


 


3.       Attached
hereto as Exhibit B are true, correct and complete copies of the resolutions duly adopted by the Board of Directors of
the Company on ______, 2020, at which a quorum was present and acting throughout. Such resolutions have not been amended, modified
or rescinded and remain in full force and effect and such resolutions are the only resolutions adopted by the Company’s
Board of Directors, or any committee thereof, or the stockholders of the Company relating to or affecting (i) the entering into
and performance of the Purchase Agreement, or the issuance, offering and sale of the Purchase Shares and the Commitment Shares
and (ii) and the performance of the Company of its obligation under the Transaction Documents as contemplated therein.


 


4.       As
of the date hereof, the authorized, issued and reserved capital stock of the Company is as set forth on Exhibit C hereto.


 


IN
WITNESS WHEREOF, I have hereunder signed my name on this [___] day of [______], 202[__].


 


	 	 
	 	[________________]
	 	Secretary


 


The
undersigned as Chief Financial Officer of TODOS MEDICAL LTD., a State of Israel corporation, hereby certifies that [_________________________]
is the duly elected, appointed, qualified and acting Secretary of TODOS MEDICAL LTD., and that the signature appearing
above is his genuine signature.


 


	 	 
	 	[________________]
	 	Chief
    Financial Officer


 




    	 



    	 



    

 


EXHIBIT
D


 


FORM
OF LETTER TO THE TRANSFER AGENT FOR THE ISSUANCE OF THE INITIAL PURCHASE SHARES AND THE COMMITMENT SHARES AT SIGNING OF THE PURCHASE
AGREEMENT


 


[COMPANY
LETTERHEAD]


 


August
__, 2020


 


Worldwide
Stock Transfer, LLC


1
University Plaza Drive #505


Hackensack,
NJ 07601


Attention:
Yonah Kopstick


 


Re:
Issuance of Ordinary Shares to Lincoln Park Capital Fund, LLC


 


Dear
Mr. Kopstick:


 


On
behalf of TODOS MEDICAL LTD. (the “Company”), you are hereby instructed to issue as soon as possible
a book-entry statement representing an aggregate of 9,250,000 Ordinary Shares in the name of Lincoln
Park Capital Fund, LLC. The book-entry statement should be dated August __, 2020. I have included a true and correct copy
of resolutions duly adopted by the Company’s Board of Directors approving the issuance of these shares. The book-entry statement
should bear the following restrictive legend:


 


THE
SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES
LAWS. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE
OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES
LAWS, UNLESS SOLD PURSUANT TO: (1) RULE 144 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (2) AN OPINION OF HOLDER’S
COUNSEL, IN A CUSTOMARY FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR APPLICABLE STATE SECURITIES LAWS.


 


The
book-entry statement should be sent as soon as possible via overnight mail to the following address:


 


Lincoln
Park Capital Fund, LLC


440
North Wells, Suite 410


Chicago,
IL 60654


Attention:
Josh Scheinfeld/Jonathan Cope


 


Thank
you very much for your help. Please call me at (650) 862-5391 if you have any questions or need anything further.


 


	TODOS
    MEDICAL LTD.	 
	 	 
	By:	 	 
	Name:	Gerald
    Commissiong	 
	Title:	Chief
    Executive Officer